var title_f14_54_15200="SCC in Hodgkins disease";
var content_f14_54_15200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spinal cord compression due to Hodgkin's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A firm, white epidural mass strangles the cord at the thoracic level in a 32-year-old woman who developed hypesthesias of the lower extremities in the terminal phase of a seven-year course of Hodgkin's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Burger PC. Surgical Pathology of the Nervous System and its Coverings. 3rd edition. Burger PC, Scheithauer BW, Vogel FS. Churchill Livingstone 1991. p. 584, Figure 8.33.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15200=[""].join("\n");
var outline_f14_54_15200=null;
var title_f14_54_15201="Niflumic acid: International drug information";
var content_f14_54_15201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Niflumic acid: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actol (AT, DE, ES);",
"     </li>",
"     <li>",
"      Donalgin (HU);",
"     </li>",
"     <li>",
"      Felalgyl (FR);",
"     </li>",
"     <li>",
"      Flogovital (AR);",
"     </li>",
"     <li>",
"      Flunir (FR);",
"     </li>",
"     <li>",
"      Niflactol (ES);",
"     </li>",
"     <li>",
"      Niflam (IT);",
"     </li>",
"     <li>",
"      Niflugel (BE, CH, CZ, FR);",
"     </li>",
"     <li>",
"      Nifluril (BE, CH, CZ, FR, LU, PT);",
"     </li>",
"     <li>",
"      Sabrinin (AT);",
"     </li>",
"     <li>",
"      Sepvadol (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Niflumic Acid Glycinamide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), COX-2 Selective",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anti-inflammatory used in musculoskeletal and joint disorders",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: 250 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream: 3% (120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 2.5% (60 g)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10442 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15201=[""].join("\n");
var outline_f14_54_15201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303440\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979697\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979699\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979702\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979698\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821095\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979701\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10442\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10442|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_54_15202="Sites pelvic organ support";
var content_f14_54_15202=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Pelvic organ support quantitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Six sites (points Aa, Ba, C, D, Bp, Ap), genital hiatus (gh), perineal body (pb), and total vaginal length (tvl) used for pelvic organ support quantitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Bump, RC, Mattiasson, A, B&Oslash;, K, et al, Am J Obstet Gynecol 1996; 175:10. Copyright &copy;1996 Mosby, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15202=[""].join("\n");
var outline_f14_54_15202=null;
var title_f14_54_15203="Hypothyroidism (underactive thyroid)";
var content_f14_54_15203=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/54/15203/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15203/contributors\" id=\"au5549\">",
"       Douglas S Ross, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/54/15203/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15203/contributors\" id=\"se4042\">",
"       David S Cooper, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/54/15203/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15203/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?14/54/15203?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HYPOTHYROIDISM OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Hypothyroidism is a condition in which the thyroid gland does not produce enough thyroid hormone. It is the most common thyroid disorder.",
"    </p>",
"    <p>",
"     This topic discusses HYPOthyroidism. HYPERthyroidism is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"      \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS THE THYROID?",
"     </span>",
"    </p>",
"    <p>",
"     The thyroid is a butterfly-shaped gland in the middle of the neck, located below the larynx (voice box) and above the clavicles (collarbones) (",
"     <a class=\"graphic graphic_figure graphicRef66834 \" href=\"UTD.htm?14/43/15024\">",
"      figure 1",
"     </a>",
"     ). The thyroid produce two hormones, triiodothyronine (T3) and thyroxine (T4), which regulate how the body uses and stores energy (also known as the body's metabolism).",
"    </p>",
"    <p>",
"     Thyroid function is controlled by a gland in the brain, known as the pituitary (",
"     <a class=\"graphic graphic_figure graphicRef67279 \" href=\"UTD.htm?26/50/27424\">",
"      figure 2",
"     </a>",
"     ). The pituitary produces thyroid stimulating hormone (TSH), which stimulates the thyroid to produce T3 and T4.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HYPOTHYROIDISM CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     In about 95 percent of cases, hypothyroidism is due to a problem in the thyroid gland itself and is called primary hypothyroidism. However, certain medications and diseases can also decrease thyroid function. As an example, HYPOthyroidism can also develop after medical treatments for HYPERthyroidism, such as thyroidectomy (surgical removal of the thyroid) or radioactive iodine treatment (to destroy thyroid tissue). In some cases, hypothyroidism is a result of decreased production of thyroid-stimulating hormone (TSH) by the pituitary gland. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"      \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Thyroid problems are more common in women, increase with age, and are more common in whites and Mexican Americans than in blacks.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      HYPOTHYROIDISM SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of hypothyroidism vary widely; some people have no symptoms while others have dramatic symptoms or, rarely, life-threatening symptoms. The symptoms of hypothyroidism are notorious for being nonspecific and for mimicking many of the normal changes of aging. Usually, symptoms are milder when hypothyroidism develops gradually.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      General symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Thyroid hormone normally stimulates the metabolism, and most of the symptoms of hypothyroidism reflect slowing of metabolic processes. General symptoms may include fatigue, sluggishness, weight gain, and intolerance of cold temperatures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Skin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hypothyroidism can decrease sweating. The skin may become dry and thick. The hair may become coarse or thin, eyebrows may disappear, and nails may become brittle.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Eyes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hypothyroidism can lead to mild swelling around the eyes. People who develop hypothyroidism after treatment for Graves' disease may retain some of the eye symptoms of Graves' disease, including protrusion of the eyes, the appearance of staring, and impaired movement of the eyes. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"      \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Cardiovascular system",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hypothyroidism slows the heart rate and weakens the heart's contractions, decreasing its overall function. Related symptoms may include fatigue and shortness of breath with exercise. These symptoms may be more severe in people who also have heart disease. In addition, hypothyroidism can cause mild high blood pressure and raise blood levels of cholesterol.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Respiratory system",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hypothyroidism weakens the respiratory muscles and decreases lung function. Symptoms can include fatigue, shortness of breath with exercise, and decreased ability to exercise. Hypothyroidism can also lead to swelling of the tongue, hoarse voice, and sleep apnea. Sleep apnea is a condition in which there is intermittent blockage of the airway while sleeping, causing fitful sleep and daytime sleepiness. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"      \"Patient information: Sleep apnea in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Gastrointestinal system",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hypothyroidism slows the actions of the digestive tract, causing constipation. Rarely, the digestive tract may stop moving entirely. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      \"Patient information: Constipation in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Reproductive system",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with hypothyroidism often have menstrual cycle irregularities, ranging from absent or infrequent periods to very frequent and heavy periods. The menstrual irregularities can make it difficult to become pregnant, and pregnant women with hypothyroidism have an increased risk for miscarriage during early pregnancy. Treatment of hypothyroidism can decrease these risks. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"      \"Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Myxedema coma",
"     </span>",
"     &nbsp;&mdash;&nbsp;In people with severe hypothyroidism, trauma, infection, exposure to the cold, and certain medications can rarely trigger a life-threatening condition called myxedema coma, which causes a loss of consciousness and hypothermia (low body temperature).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      HYPOTHYROIDISM DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     In the past, hypothyroidism was not diagnosed until symptoms had been present for a long time. However, simple blood tests can now detect hypothyroidism at an early stage. A person may be tested for hypothyroidism if there are signs and symptoms, such as those discussed above, or as a screening test.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood tests can confirm the diagnosis and pinpoint the underlying cause of the thyroid hormone deficiency. The most common blood test for hypothyroidism is TSH (thyroid stimulating hormone). TSH is the most sensitive test because it can be elevated even with small decreases in thyroid function. Thyroxine (T4), the main product of the thyroid gland, may also be measured to confirm and assess the degree of hypothyroidism.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Routine screening",
"     </span>",
"     &nbsp;&mdash;&nbsp;All newborn babies in the United States are routinely screened for thyroid hormone deficiency. It is not clear if all adults should be tested for thyroid disease [",
"     <a class=\"abstract\" href=\"UTD.htm?14/54/15203/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      HYPOTHYROIDISM TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The goal of treatment for hypothyroidism is to return blood levels of TSH and T4 to the normal range and to alleviate symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Medication",
"     </span>",
"     &nbsp;&mdash;&nbsp;The treatment for hypothyroidism is thyroid hormone replacement therapy. This is usually given as an oral form of T4. T4 should be taken once per day on an empty stomach (one hour before eating or two hours after). Generic (levothyroxine) and brand-name (Synthroid&reg;, Levoxyl&reg;, Levothroid&reg;, Unithyroid&reg;) formulations are equally effective. However, it is preferable to stay on the same type of T4 rather than switching between brand name",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     generic formulations.",
"    </p>",
"    <p>",
"     If a switch is necessary, a blood test is usually done six weeks later to determine if the dose needs to be adjusted. Color-coded tablets can help with dose adjustments.",
"    </p>",
"    <p>",
"     Some clinicians prescribe another form of thyroid hormone, triiodothyronine (T3) in combination with T4. However, since T4 is converted into T3 in other organs, the majority of studies have not shown an advantage of combination T3 and T4 therapy over T4 alone.",
"    </p>",
"    <p>",
"     In most cases, symptoms of hypothyroidism begin to improve within two weeks of starting thyroid replacement therapy. However, people with more severe symptoms may require several months of treatment before they fully recover.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Duration and dose",
"     </span>",
"     &nbsp;&mdash;&nbsp;A healthcare provider will prescribe an initial dose of T4 and then retest the blood level of TSH after six weeks. The T4 dose can be adjusted at that time, depending upon these results. This process may be repeated several times before hormone levels become normal. After the optimal dose is identified, a provider may recommend monitoring blood tests once yearly, or more often as needed. Most people with hypothyroidism require lifelong treatment, although the dose of T4 may need to be adjusted over time.",
"    </p>",
"    <p>",
"     Never increase or decrease the T4 dose without first consulting a healthcare provider. Overreplacement of T4 can cause mild hyperthyroidism, with the associated dangers of atrial fibrillation (irregular heart beat) and, possibly, accelerated bone loss (osteoporosis).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Dose changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Changes in the T4 dose are based upon the person's TSH and T4 level. The dose may need to be increased if thyroid disease worsens, during pregnancy, if gastrointestinal conditions impair T4 absorption, or if the person gains weight. A high fiber diet, calcium- or aluminum-containing antacids, and iron tablets can interfere with the absorption of T4 and should be taken at a different time of day.",
"    </p>",
"    <p>",
"     The dose may need to be decreased as the person gets older, after childbirth, or if the person loses weight.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;Individual T4 doses can vary widely and depend upon a variety of factors, including the underlying cause of hypothyroidism. People with certain conditions require more frequent monitoring.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Advanced age and heart disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Thyroid hormone makes the heart work a bit harder. Therefore, a clinician may opt for more conservative T4 treatment in older adults and in people with coronary artery disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women often need higher doses of T4 during pregnancy. Testing is usually recommended every four weeks, beginning after conception. Once the optimal T4 dose is established, testing is usually repeated at least once per trimester. After delivery, the woman's dose of T4 will need to be adjusted again.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hypothyroidism can increase the risk of certain surgery-related complications; bowel function may be slow to recover and infection may be overlooked if there is no fever. If pre-operative blood tests reveal low thyroid hormone levels, non-emergency surgery is usually postponed until treatment has returned T4 levels to normal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Hypothyroidism without symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some cases, hypothyroidism is extremely mild or causes no obvious symptoms (called subclinical hypothyroidism). The decision to treat subclinical hypothyroidism with T4 is controversial. Many experts treat patients with subclinical hypothyroidism if their TSH is &gt;10",
"     <span class=\"nowrap\">",
"      mU/L",
"     </span>",
"     to prevent the development of hypothyroidism and associated symptoms. Treatment is also recommended for people who have a goiter or nonspecific symptoms of hypothyroidism, such as fatigue, constipation, or depression.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287556329\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3053334679\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=see_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=see_link\">",
"      Patient information: Hemochromatosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23618?source=see_link\">",
"      Patient information: Thyroid nodules (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/34/27170?source=see_link\">",
"      Patient information: Congenital hypothyroidism (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/18/6434?source=see_link\">",
"      Patient information: Hypoparathyroidism (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/10/38050?source=see_link\">",
"      Patient information: Panhypopituitarism (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/50/5922?source=see_link\">",
"      Patient information: Thyroiditis after pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/42/13986?source=see_link\">",
"      Patient information: Thyroiditis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3053334716\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      Patient information: Constipation in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"      Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=see_link\">",
"      Cardiovascular effects of hypothyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"      Central hypothyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=see_link\">",
"      Growth failure after childhood cancer: Role of hypothyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=see_link\">",
"      Myxedema coma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36585?source=see_link\">",
"      Neurologic manifestations of hypothyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15081?source=see_link\">",
"      Treatment and prognosis of congenital hypothyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Thyroid Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.thyroid.org/\">",
"      www.thyroid.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/thyroid.cfm\">",
"      www.hormone.org/public/thyroid.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Thyroid Conditions Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://thyroid.about.com/forum\">",
"      file://thyroid.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?14/54/15203/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?14/54/15203?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15203/abstract/1\">",
"      U.S. Preventive Services Task Force. Screening for thyroid disease: recommendation statement. Ann Intern Med 2004; 140:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15203/abstract/2\">",
"      Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291:228.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f14_54_15203=[""].join("\n");
var outline_f14_54_15203=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HYPOTHYROIDISM OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS THE THYROID?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HYPOTHYROIDISM CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           HYPOTHYROIDISM SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           HYPOTHYROIDISM DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           HYPOTHYROIDISM TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\" title=\"figure 1\">",
"           Thyroid anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/50/27424\" title=\"figure 2\">",
"           Endocrine glands PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f14_54_15204="Fluticasone (topical): Patient drug information";
var content_f14_54_15204=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluticasone (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44340?source=see_link\">",
"     see \"Fluticasone (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/7/27764?source=see_link\">",
"     see \"Fluticasone (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9349371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cutivate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9349372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cutivate&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10031102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702152",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fluticasone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2935400",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to formaldehyde.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701382",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a skin infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11691 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15204=[""].join("\n");
var outline_f14_54_15204=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349371\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349372\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031102\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031104\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031103\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031108\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031109\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031111\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031106\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031107\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031112\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031113\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/3/30773?source=related_link\">",
"      Fluticasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/5/28756?source=related_link\">",
"      Fluticasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/45/32468?source=related_link\">",
"      Fluticasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26120?source=related_link\">",
"      Fluticasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/33/12822?source=related_link\">",
"      Fluticasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/29/25047?source=related_link\">",
"      Fluticasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44340?source=related_link\">",
"      Fluticasone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/7/27764?source=related_link\">",
"      Fluticasone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_54_15205="Bladder cancer treatment; invasive cancer";
var content_f14_54_15205=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/54/15205/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15205/contributors\" id=\"au2298\">",
"       Andrew J Stephenson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/54/15205/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15205/contributors\" id=\"se2767\">",
"       Seth P Lerner, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/54/15205/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15205/contributors\" id=\"de8229\">",
"       Don S Dizon, MD, FACP",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?14/54/15205?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BLADDER CANCER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The optimal treatment for urothelial (transitional cell) bladder cancer depends upon the cancer's stage and grade, and also on the health of the patient.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Approximately 70 percent of all new cases of bladder cancer are classified as non-muscle-invasive or superficial. The initial treatment for superficial bladder cancer is surgical removal of the tumor through a cystoscope (called transurethral resection of bladder tumor, or TURBT). This is often followed by adjuvant (additional) therapy, which reduces the chances of the cancer recurring. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?13/39/13939?source=see_link\">",
"        \"Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       The remaining 30 percent are invasive bladder cancers, and generally require surgical removal of the bladder (cystectomy) and some surrounding organs.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This article will review the treatment of invasive urothelial bladder cancer. The diagnosis and staging of bladder cancer and the treatment of superficial bladder cancer are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/12/31939?source=see_link\">",
"      \"Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/39/13939?source=see_link\">",
"      \"Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS INVASIVE BLADDER CANCER?",
"     </span>",
"    </p>",
"    <p>",
"     Bladder tumors are staged using the TNM system, which indicates how deeply the tumor has penetrated (T stage), whether it has reached the nodes (N), and whether it has spread or metastasized to other parts of the body (M); these stages are then grouped as 0 through IV, and this helps the doctor to decide what type of treatment to use.",
"    </p>",
"    <p>",
"     Invasive bladder cancer is stage T1 or greater, meaning that the tumor has invaded the lining of the bladder. If the tumor has invaded the muscle layer of the bladder, it is stage T2. Stage T3 cancer has grown through the bladder muscle into the fat layer surrounding the bladder, while stage T4 cancer has spread to nearby organs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      BLADDER CANCER TREATMENT OPTIONS",
"     </span>",
"    </p>",
"    <p>",
"     The standard treatment for muscle-invasive bladder cancer includes surgery to remove the bladder and nearby organs (called radical cystectomy). Lower stage invasive bladder cancer (stage T1 tumors) may be treated with radical cystectomy or intravesical BCG. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/39/13939?source=see_link&amp;anchor=H7#H7\">",
"      \"Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)\", section on 'Intravesical BCG'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Radical cystectomy requires the creation of a new way to get rid of urine. (See",
"     <a class=\"local\" href=\"#H9\">",
"      'Where will the urine go?'",
"     </a>",
"     below.) In some cases, it is possible to avoid cystectomy by having a bladder preserving treatment. However, this treatment is not an option for most people with muscle-invasive bladder cancer due to the high risk that the cancer will come back (called a recurrence).",
"    </p>",
"    <p>",
"     For patients with muscle-invasive bladder cancer who are able to tolerate more aggressive treatment, chemotherapy is often given before surgery (called neoadjuvant chemotherapy).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Which treatment is best?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The best treatment for invasive bladder cancer depends upon the person's age, underlying medical problems, stage of the bladder cancer, and personal preference. When possible, surgical removal of the bladder is preferred because it has a lower chance of cancer recurrence and better chance of survival compared to other treatments. However, preserving the bladder may be an option in selected cases.",
"    </p>",
"    <p>",
"     Cystectomy is preferred for patients who have:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Invasive bladder cancer and are not candidates for bladder preservation",
"      </li>",
"      <li>",
"       Low-stage or superficial cancers that have recurred after intravesical BCG",
"      </li>",
"      <li>",
"       High-grade T1 cancers (intravesical BCG is a reasonable alternative)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Bladder preservation may be an option for patients who:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Are elderly or who have serious underlying medical problems and would not be able to tolerate a major surgery",
"      </li>",
"      <li>",
"       Strongly prefer to keep their bladder AND have a single, well-defined, muscle-invasive tumor inside the bladder, without any evidence of carcinoma in situ (which often recurs) or hydronephrosis (enlargement of the kidneys)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      CYSTECTOMY (SURGICAL REMOVAL OF THE BLADDER)",
"     </span>",
"    </p>",
"    <p>",
"     Patients with muscle-invasive bladder cancer who need to have cystectomy are sometimes advised to have chemotherapy before surgery, if the patient is healthy enough to tolerate this more aggressive treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Neoadjuvant chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy refers to the use of medicines to stop or slow the growth of cancer cells. Chemotherapy works by interfering with the ability of rapidly growing cells (such as cancer cells) to divide or reproduce themselves. Because most of an adult's normal cells are not rapidly growing, they are not affected by chemotherapy. Exceptions to this include cells of the bone marrow (where the blood cells are produced), the hair, and the lining of the gastrointestinal tract. These tissues are affected most by chemotherapy, causing the typical side effects (low blood counts, hair loss, etc).",
"    </p>",
"    <p>",
"     Neoadjuvant chemotherapy is the term used to describe chemotherapy given before surgery. When possible, people with muscle-invasive bladder cancer are usually advised to have neoadjuvant chemotherapy before cystectomy.",
"    </p>",
"    <p>",
"     The reason for this recommendation is that chemotherapy helps to eliminate undetectable cancer cells that are often found in other areas of the body in people with invasive cancer. By eliminating these cancer cells, chemotherapy helps to improve survival. Clinical trials have shown that neoadjuvant chemotherapy reduces the risk of death and improves five-year survival in people with invasive bladder cancer [",
"     <a class=\"abstract\" href=\"UTD.htm?14/54/15205/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     The chemotherapy regimen usually includes a combination of four drugs: methotrexate, vinblastine, doxorubicin, and cisplatin (abbreviated MVAC). The regimen is usually given into a vein during the daytime. Occasionally, the patient may require an overnight stay in the hospital for the chemotherapy treatments. During the first two days, all of the medications are given together. Methotrexate and vincristine are then given again 15 and 22 days later. This is referred to as one cycle. A new cycle is started one week later.",
"    </p>",
"    <p>",
"     A cycle of chemotherapy refers to the time it takes to give the treatment and then allow the body to recover from the effects. During this time, patients are closely monitored for signs of drug toxicity and side effects. Three cycles of MVAC are usually recommended before cystectomy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Chemotherapy side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effects of MVAC include fatigue, increased risk of infection, bruising or bleeding easily, complete hair loss, mouth soreness, nausea or vomiting (usually can be prevented or treated), decreased hearing or ringing in the ears, numbness or tingling in the hands or feet, and pink-red colored urine. These side effects are usually temporary and resolve after treatment is completed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Cystectomy procedure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radical cystectomy includes removal of the bladder, nearby organs, and associated lymph nodes.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In men, radical cystectomy generally includes removal of the bladder, as well as the prostate, and seminal vesicles (",
"       <a class=\"graphic graphic_figure graphicRef51018 \" href=\"UTD.htm?21/28/21955\">",
"        figure 1",
"       </a>",
"       ). Because of the extent of the surgery, nerve damage can occur, leading to erectile dysfunction (inability to have or maintain an erection). (See",
"       <a class=\"local\" href=\"#H12\">",
"        'Nerve-sparing procedures'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       In females, radical cystectomy includes removal of the bladder, as well as the uterus, cervix, and upper vagina (",
"       <a class=\"graphic graphic_figure graphicRef54274 \" href=\"UTD.htm?35/35/36403\">",
"        figure 2",
"       </a>",
"       ).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Where will the urine go?",
"     </span>",
"     &nbsp;&mdash;&nbsp;After the bladder is removed, the surgeon must create a new place for urine to be collected. This is called a urinary diversion. All options involve using a segment of bowel, which is removed from the small or large intestine. After removing a segment of bowel, the intestines are reattached so that they function normally. The section of bowel that is removed is cleaned and prepared.",
"    </p>",
"    <p>",
"     There are several possible options at this point:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Urine can be diverted through a segment of bowel to the skin's surface, where an opening (called a stoma) is created. A bag is attached to the stoma to collect the urine. This is called a non-continent cutaneous diversion or ileoconduit (",
"       <a class=\"graphic graphic_figure graphicRef69024 \" href=\"UTD.htm?28/54/29536\">",
"        figure 3",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       A reservoir (like a pouch) may be created under the skin of the abdomen using tissue from the stomach or intestines. Urine collects in the pouch, and the patient uses a catheter (a thin tube) to empty the pouch periodically. It is not necessary to wear a bag. This is called a continent cutaneous diversion, commonly called an Indiana pouch (",
"       <a class=\"graphic graphic_figure graphicRef70318 \" href=\"UTD.htm?2/1/2065\">",
"        figure 4",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       A new bladder may be created from a segment of bowel. The new bladder is connected to the urethra, allowing the person to urinate normally. This is called an orthotopic neobladder, commonly called a Studer neobladder or pouch (",
"       <a class=\"graphic graphic_figure graphicRef78209 \" href=\"UTD.htm?16/20/16705\">",
"        figure 5",
"       </a>",
"       ).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The \"best\" type of urinary diversion depends upon the patient and surgeon's preference, as well as the extent of the cancer. In addition, the continent reservoir and neobladder require the person to learn how to self-catheterize; patients who would have difficulty handling or placing the catheter may not be good candidates for these procedures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Complications of urinary diversion",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some of the potential complications of urinary diversion include leakage of urine, urinary tract infection, skin irritation (with stoma or pouch), and narrowing or closure of the tissue where urine exits. The risk of each of these depends upon which procedure is performed. To understand the risks and benefits of each type of diversion, talk with your surgeon.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Lymph node removal",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lymph fluid from the bladder normally drains into lymph nodes (glands) located in the pelvis. If the cancer has spread to lymph nodes, there is a much higher risk that the cancer has also spread elsewhere. This significantly increases the risk of the cancer recurring at a later time.",
"    </p>",
"    <p>",
"     An important part of radical cystectomy is removal of all lymph nodes that could contain tumor cells. This includes lymph nodes in the pelvic region, and in some cases, also includes more distant lymph node groups. The patient should talk to his or her surgeon about which nodes will be removed as there is increasing evidence that removing more lymph node groups (rather than the standard groups) may improve survival [",
"     <a class=\"abstract\" href=\"UTD.htm?14/54/15205/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Nerve-sparing procedures",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Men",
"     </span>",
"     &nbsp;&mdash;&nbsp;In men, surgical removal of the prostate and seminal vesicles (",
"     <a class=\"graphic graphic_figure graphicRef51018 \" href=\"UTD.htm?21/28/21955\">",
"      figure 1",
"     </a>",
"     ) can damage the nerves responsible for achieving and maintaining an erection. Men who want to preserve their ability to have an erection are sometimes able to have a nerve-sparing surgery, which reduces the risk of nerve damage. This procedure is only available to men who have no evidence of cancer in the bladder neck or prostatic urethra, no carcinoma in situ, and no evidence of prostate cancer.",
"    </p>",
"    <p>",
"     About 30 to 50 percent of men who have nerve-sparing cystectomy are able to have an erection sufficient for sexual intercourse one to two years after surgery [",
"     <a class=\"abstract\" href=\"UTD.htm?14/54/15205/abstract/3\">",
"      3",
"     </a>",
"     ]. Most of these men will require an oral medication, such as sildenafil (Viagra&reg;), to have an erection. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"      \"Patient information: Sexual problems in men (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     One potential risk of nerve-sparing surgery is that an insufficient amount of cancerous tissue will be removed from around the nerves. However, several studies have shown that bladder cancer recurrence rates are similar in men who have nerve-sparing and traditional radical cystectomy when patients are carefully screened before surgery [",
"     <a class=\"abstract\" href=\"UTD.htm?14/54/15205/abstract/4\">",
"      4",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Women",
"     </span>",
"     &nbsp;&mdash;&nbsp;In women, nerve-sparing surgery involves careful removal of tissue on each side of the vagina, where nerves responsible for sexual function are found. Nerve-sparing surgery may help to prevent vaginal dryness, pain with intercourse, and loss of the ability to have orgasm.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Surgical complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Up to 60 percent of patients who have radical cystectomy and urinary diversion develop some type of complication. The most common serious complications include infection, wound opening, bleeding, and blood clots in the lungs (pulmonary embolus). The surgeon's and hospital's experience in performing cystectomy, as well as the patient's age and any underlying medical problems, affect the risk of developing complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Chemotherapy after cystectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some situations, chemotherapy is not given before cystectomy. However, chemotherapy may be recommended after surgery (called adjuvant chemotherapy) if more extensive disease is found when the bladder is removed. For example, chemotherapy may be recommended after cystectomy for those healthy enough to tolerate it if:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The tumor extends into the perivesical fat surrounding the bladder (tumor stage T3 or higher)",
"      </li>",
"      <li>",
"       Lymph nodes in the region are positive",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The best chemotherapy regimen is not clear; patients are encouraged to enroll in a clinical trial if possible. (See",
"     <a class=\"local\" href=\"#H23\">",
"      'Clinical trials'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Outcomes",
"     </span>",
"     &nbsp;&mdash;&nbsp;The outcomes following radical cystectomy for bladder cancer depend upon the stage and extent the cancer and lymph node involvement [",
"     <a class=\"abstract\" href=\"UTD.htm?14/54/15205/abstract/5\">",
"      5",
"     </a>",
"     ]. Talk to your doctor or nurse if you have questions about your cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      BLADDER PRESERVATION",
"     </span>",
"    </p>",
"    <p>",
"     In selected people with invasive bladder cancer, it may be possible to avoid removing the entire bladder. The possible risk of this approach is that the bladder cancer may be more likely to recur.",
"    </p>",
"    <p>",
"     Bladder preservation options include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Radical transurethral resection of bladder tumor (TURBT)",
"      </li>",
"      <li>",
"       Partial removal of the bladder",
"      </li>",
"      <li>",
"       Chemotherapy and radiation (chemoradiotherapy), which are performed after radical TUR",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Risk of recurrence with bladder preservation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Between 30 to 60 percent of patients who have bladder preservation will develop recurrent bladder tumors, approximately half of which are invasive. If this occurs, the recommended treatment is immediate cystectomy.",
"    </p>",
"    <p>",
"     Overall survival in patients who develop a recurrence and then undergo cystectomy is 40 to 50 percent; this is probably 10 to 20 percent lower compared to immediate treatment with radical cystectomy. This is important to consider when deciding upon a treatment plan.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Radical transurethral resection of bladder tumor (TURBT)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radical TURBT is a procedure in which a physician uses a cystoscope to view the lining of the bladder and remove any abnormal-appearing areas. This is similar to the procedure used to treat superficial bladder cancer.",
"    </p>",
"    <p>",
"     However, radical TURBT is a more aggressive than standard TURBT; the physician will remove any abnormal appearing areas as well as the underlying bladder muscle down to the layer of fat surrounding the bladder (called perivesical fat).",
"    </p>",
"    <p>",
"     Several weeks after the radical TURBT, the physician will use the cystoscope to look inside the bladder again. If there is no evidence of cancer, the patient will be followed closely.",
"    </p>",
"    <p>",
"     If there is evidence of cancer, surgical removal of the bladder is usually recommended, sometimes with neoadjuvant chemotherapy given before surgery. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Cystectomy procedure'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Partial bladder removal (cystectomy)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Partial cystectomy is a surgical procedure in which the bladder tumor and some surrounding bladder tissue are removed, allowing the person to keep the healthy tissue. The surgery is done through a midline (up and down) incision in the lower abdomen. Removal of involved lymph nodes is also performed. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Lymph node removal'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     Partial cystectomy is not an option for most people, but may be available for people with certain characteristics, including a single small tumor at the top of the bladder. People who have recurrent bladder cancer or involvement of other areas (urethra, lower bladder) are not good candidates for partial cystectomy.",
"    </p>",
"    <p>",
"     The advantage of partial cystectomy is that it allows the person to urinate \"normally\" after surgery and does not usually interfere with sexual function. The disadvantage is that there is a higher risk of bladder cancer recurrence. Approximately 70 percent of patients survive long-term after partial cystectomy [",
"     <a class=\"abstract\" href=\"UTD.htm?14/54/15205/abstract/6\">",
"      6",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Chemoradiotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemoradiotherapy is a treatment that involves having radiation therapy to the bladder and pelvis, along with chemotherapy. Removal of all visible evidence of cancer with TURBT is recommended before proceeding to chemoradiation. Chemoradiation is less likely to be successful in patients who have residual cancer in the bladder at the start of therapy.",
"    </p>",
"    <p>",
"     Radiation therapy involves the use of focused high energy x-rays to destroy cancer cells. The x-rays are delivered from a machine that is outside of the patient. The damaging effect of radiation is cumulative, and a certain dose is required to stop the growth of cancer cells. In order to accomplish this, small radiation doses are administered for a few seconds each day (similar to having an x-ray), five days per week, for several weeks. Treatment is not painful.",
"    </p>",
"    <p>",
"     A chemotherapy drug, such as cisplatin, is usually given once every three weeks into a vein during radiation therapy. Cisplatin makes the tumor cells more sensitive to the radiation treatment, improving the chance of eliminating the cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learning/\">",
"      www.cancer.gov/clinicaltrials/learning/",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"      www.cancer.gov/clinicaltrials/",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"      file://clinicaltrials.gov/",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H170238522\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14514576\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/21/39250?source=see_link\">",
"      Patient information: Bladder cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14514591\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/39/13939?source=see_link\">",
"      Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/12/31939?source=see_link\">",
"      Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29766?source=see_link\">",
"      Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35367?source=see_link\">",
"      Chemoprevention of bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29431?source=see_link\">",
"      Experimental systemic therapy of metastatic bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/39/5749?source=see_link\">",
"      Laparoscopic/robotic-assisted radical cystectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=see_link\">",
"      Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=see_link\">",
"      Nonurothelial bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27481?source=see_link\">",
"      Pathology of bladder neoplasms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/39/634?source=see_link\">",
"      Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22039?source=see_link\">",
"      Screening for bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32298?source=see_link\">",
"      Urinary diversion and reconstruction following cystectomy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/types/bladder\">",
"      www.cancer.gov/cancertopics/types/bladder",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/bladdercancer.html\">",
"      www.nlm.nih.gov/medlineplus/bladdercancer.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Raghavan D, Tuthill K. Bladder Cancer: A Cleveland Clinic Guide for Patients, Cleveland Clinic",
"       <span class=\"nowrap\">",
"        Press/Kaplan",
"       </span>",
"       Press, Cleveland 2008.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?14/54/15205/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?14/54/15205?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15205/abstract/1\">",
"      Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15205/abstract/2\">",
"      Leissner J, Ghoneim MA, Abol-Enein H, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 2004; 171:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15205/abstract/3\">",
"      Kessler TM, Burkhard FC, Perimenis P, et al. Attempted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution. J Urol 2004; 172:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15205/abstract/4\">",
"      Schoenberg MP, Walsh PC, Breazeale DR, et al. Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup. J Urol 1996; 155:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15205/abstract/5\">",
"      Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15205/abstract/6\">",
"      Holzbeierlein JM, Lopez-Corona E, Bochner BH, et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 2004; 172:878.",
"     </a>",
"    </li>",
"    <li>",
"     Raghavan D, Tuthill K. Bladder Cancer (Cleveland Clinic Guide), Bladder Cancer (Cleveland Clinic Guide), Cleveland 2008.",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f14_54_15205=[""].join("\n");
var outline_f14_54_15205=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BLADDER CANCER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS INVASIVE BLADDER CANCER?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           BLADDER CANCER TREATMENT OPTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           CYSTECTOMY (SURGICAL REMOVAL OF THE BLADDER)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           BLADDER PRESERVATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/28/21955\" title=\"figure 1\">",
"           Male cystectomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/35/36403\" title=\"figure 2\">",
"           Female cystectomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/54/29536\" title=\"figure 3\">",
"           Non-continent cutaneous diversion PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/1/2065\" title=\"figure 4\">",
"           Cutaneous continent reservoir PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/20/16705\" title=\"figure 5\">",
"           Neobladder PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f14_54_15206="Temporomandibular joint TMJ anatomy";
var content_f14_54_15206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Temporomandibular joint (TMJ) anatomy and associated musculature",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 682px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Temporomandibular joint (TMJ), associated muscles of mastication, and cervical muscles that connect the mandible and head and neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15206=[""].join("\n");
var outline_f14_54_15206=null;
var title_f14_54_15207="Trichinellosis";
var content_f14_54_15207=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Trichinellosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/54/15207/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15207/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15207/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/54/15207/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15207/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/54/15207/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15207/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/54/15207/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trichinellosis (trichinosis) is a parasitic infection caused by nematodes (roundworms) of the genus Trichinella. Pigs are the most important source of human infection, although a number of other animals are also epidemiologically important hosts. Consumption of raw or undercooked meat is the principal mode of transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28181411\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trichinellosis has been reported worldwide. The prevalence of human infection is highest in China, Thailand, Mexico, Argentina, Bolivia, the former Soviet Union, Romania, and other parts of Central Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are 8 species and 11 genotypes of Trichinella; these are divided into those that encapsulate in host muscle tissue of mammals only, and those that do not encapsulate and infect mammals, birds (one species), or reptiles (two species). All recognized species and genotypes can infect humans, but there are seven species of Trichinella that have been implicated in human disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T. spiralis is found worldwide in a great variety of carnivorous and omnivorous animals.",
"     </li>",
"     <li>",
"      T. nativa is found in arctic regions and infects bears, foxes, and walruses.",
"     </li>",
"     <li>",
"      T. nelsoni is present in Africa, south of the Sahara, where it is common in felid predators and scavenger animals, such as hyenas and bush pigs.",
"     </li>",
"     <li>",
"      T. britovi is found in temperate areas of Europe, western Asia, and",
"      <span class=\"nowrap\">",
"       western/southern",
"      </span>",
"      Africa in carnivores but not domestic swine.",
"     </li>",
"     <li>",
"      T. pseudospiralis is found in mammals and birds worldwide [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      T. murelli is found in wild mammals in the United States and Japan [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      T. papuae is found in Papua New Guinea in domestic and feral pigs [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/7\">",
"       7",
"      </a>",
"      ]. It has also been reported from Thailand [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/8,9\">",
"       8,9",
"      </a>",
"      ] and Taiwan [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One additional species, T. zimbabwensis, has been described in crocodiles in Tanzania [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/11\">",
"     11",
"    </a>",
"    ]. The clinical importance of the additional known genotypes of Trichinella is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/3\">",
"     3",
"    </a>",
"    ]. Information on species and genotype distribution and host range can be downloaded from the International Trichinella Reference Centre [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cattle are herbivores so are not naturally infected, although beef can become contaminated with Trichinella larvae from pork during processing. Horse meat has also been associated with outbreaks of trichinellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/13\">",
"     13",
"    </a>",
"    ]. Since Trichinella infection in humans is strongly associated with the consumption of raw or undercooked meat, cultural factors and food preferences play an important role in the epidemiology of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, 66 cases of trichinellosis were reported between 2002 and 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/15\">",
"     15",
"    </a>",
"    ]. Clusters of cases tend to occur among groups that have consumed meat from a common infected animal. As a result of improvements in swine production, trichinellosis has declined steadily in the United States. However, undercooked wild game, predominantly bear meat, has emerged as a predominant source for infection with Trichinella [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28181427\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life cycle consists of two components: a domestic cycle and a sylvatic cycle (",
"    <a class=\"graphic graphic_figure graphicRef51088 \" href=\"UTD.htm?0/52/839\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/14\">",
"     14",
"    </a>",
"    ]. The domestic cycle usually involves pigs and rodents; other domestic animals, such as horses, can be involved. The sylvatic cycle can involve a broad range of infected animals; animals most often implicated as sources of human infection include bear, moose, and wild boar.",
"    <br/>",
"    <br/>",
"    Trichinellosis is caused by the ingestion of undercooked meat containing encysted larvae of Trichinella species from a domestic or sylvatic animal (except for T. pseudospiralis, T. papuae, and T. zimbabwensis, which do not encyst). The most frequent cause of infection is T. spiralis acquired by consumption of inadequately cooked pork from domestic pigs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The larvae are released from the cysts following exposure to gastric acid and pepsin. Subsequently, they invade the small bowel mucosa where they develop into adult worms (females 2.2 mm in length; males 1.2 mm). The life span in the small bowel is about four weeks. After one week, the females release larvae that migrate to striated muscles, where they encyst.",
"   </p>",
"   <p>",
"    Notably, in the Trichinella lifecycle, adult worms and encysted larvae develop within a single vertebrate host. Infected animals serve as definitive hosts as well as a potential intermediate hosts. A second host is required to perpetuate the life cycle of Trichinella.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28181732\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the severity of infection in humans correlates with the number of ingested larvae. Mild infection (less than 10",
"    <span class=\"nowrap\">",
"     larvae/g",
"    </span>",
"    of muscle) can be subclinical. The incubation period is generally 7 to 30 days; it varies with the number of ingested larvae (which correlates with how well meat has been cooked), host immune status, and species of Trichinella [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/19\">",
"     19",
"    </a>",
"    ]. Shorter incubation periods are generally associated with a more severe disease course.",
"   </p>",
"   <p>",
"    For heavy infections, two clinical stages may be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intestinal stage occurs between the second and seventh day following ingestion, when encysted larvae are liberated from the meat by gastric juices. Larvae mature into adult worms that burrow into the intestinal mucosa. Fertilized female worms release new larvae about one week after ingestion and this continues for up to five weeks, depending upon the severity of the infection. This stage may be asymptomatic or may be accompanied by symptoms including abdominal pain, nausea, vomiting, and diarrhea. Prolonged diarrhea lasting for weeks has been attributed to repeated reinfection in previously infected and sensitized patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The muscle stage develops after the first week of ingestion and represents the period when adult-derived larvae in the intestines disseminate hematogenously and enter skeletal muscle. For species other than T. pseudospiralis and T. papuae, each larva becomes encysted within a host muscle cell (",
"      <a class=\"graphic graphic_picture graphicRef56196 \" href=\"UTD.htm?19/44/20165\">",
"       picture 1",
"      </a>",
"      ); T. pseudospiralis and T. papuae larvae remain in the muscle without forming cysts. Both encysted and free Trichinella larvae remain viable for years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cardinal clinical manifestations of trichinellosis occur during the muscle phase of infection. As larvae enter skeletal muscles, muscle pain, tenderness, swelling, and weakness develop. The pain can be so extreme as to limit all movement, including breathing or moving the tongue. High fever lasting a number of weeks may be observed. Physical findings include subungual splinter hemorrhages (",
"    <a class=\"graphic graphic_picture graphicRef52141 \" href=\"UTD.htm?24/30/25056\">",
"     picture 2",
"    </a>",
"    ), conjunctival and retinal hemorrhages, periorbital edema and chemosis, visual disturbance, and ocular pain. Less common manifestations include macular or urticarial rash, headache, cough, dyspnea, and dysphagia. Hepatomegaly is occasionally observed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one outbreak of Trichinella involving 98 individuals in Turkey, the most frequent musculoskeletal symptoms reported were muscle pain (87 percent), joint pain (84 percent), subjective muscle weakness (76 percent), and diminished joint mobility (64 percent). The most frequently affected muscle groups included calves, upper arm, neck and shoulder girdle, and forearms. Muscle pain was reported more frequently in the upper than in the lower extremities. Joint pain was reported more frequently at rest than with activity. However, no objective evidence of arthritis or muscle weakness was noted on physical examination in any patient [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progressive muscle encystment is associated with resolution of clinical manifestations even though the encysted larvae remain viable. Encapsulated parasites can persist for several years before they calcify and die [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/24\">",
"     24",
"    </a>",
"    ]. T. pseudospiralis larvae do not encyst; clinical manifestations may include fatigue, postexercise weakness, and myositis that persist for several months to years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/5,25\">",
"     5,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28181701\">",
"    <span class=\"h3\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the early intestinal stage there are no specific laboratory abnormalities. Leukocytosis and eosinophilia appear during the second week of the muscle stage. Nonspecific findings include elevated serum muscle enzymes (creatine kinase and lactate dehydrogenase) and hypergammaglobulinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=see_link\">",
"     \"Muscle enzymes in the evaluation of neuromuscular diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Eosinophilia is a hallmark of clinical trichinellosis and is generally observed in most cases. The proportion of eosinophils rises to a maximum of 20 to 90 percent in the third or fourth week. There is no correlation between the clinical course of disease and the degree of eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/19\">",
"     19",
"    </a>",
"    ]. Eosinophilia may disappear in some heavily infected patients; this is considered to be a poor prognostic sign. In this setting eosinopenia is may be due to inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    superimposed bacterial infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28181672\">",
"    <span class=\"h2\">",
"     Serious infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious infections may include cardiac, central nervous system, renal,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary involvement. Fatal outcomes in acute trichinellosis usually result from myocarditis, encephalitis, or pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac involvement is not common, but it represents the most frequent cause of death in severe trichinellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/20,26-28\">",
"     20,26-28",
"    </a>",
"    ]. Larvae do not encyst in cardiac muscle, but do elicit an eosinophil-enriched inflammatory response and myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/20,29\">",
"     20,29",
"    </a>",
"    ]. In one retrospective study of 154 patients with trichinellosis, 56 percent had ECG abnormalities, mainly nonspecific ST-T wave changes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/30\">",
"     30",
"    </a>",
"    ]. However, life-threatening arrhythmias can occur and are the likely cause of death in many patients with trichinella myocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Neurologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningitis or encephalitis develop in 10 to 24 percent of patients with severe trichinellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/20,29,31\">",
"     20,29,31",
"    </a>",
"    ]. Neurologic manifestations may develop early or late, and can be diffuse or focal in nature. Headache is common and is often exacerbated by movement. CT and MRI may show multifocal small lesions located in the cerebral cortex and white matter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/32\">",
"     32",
"    </a>",
"    ]. Pathologic findings can include edema, hemorrhage, emboli, infarctions, and perivascular infiltrates in fatal cases.",
"   </p>",
"   <p>",
"    In one review of 77 Romanian patients with neurotrichinellosis, 60 percent made a complete recovery, 23 percent had sequelae, and 17 percent died. Lower eosinophil counts were observed among patients who died than patients who survived [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious pulmonary involvement in trichinellosis is rare; in one series of 856 patients with acute trichinellosis serious pulmonary involvement was observed in 6 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/34\">",
"     34",
"    </a>",
"    ]. Pulmonary involvement may result from direct larval invasion of pulmonary tissues, myositis involving respiratory muscles, or secondary pyogenic pneumonia. Respiratory symptoms can also develop as a result of congestive heart failure due to myocarditis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Larval invasion of pulmonary tissues &mdash; Early during the stage of muscle invasion when intravascular larvae are passing through the lungs, a dry, nonproductive cough is common. Chest x-ray may demonstrate patchy basilar infiltrates, small micronodular lesions, or pleural effusions. These radiographic findings generally resolve over one to two weeks. Bronchitis is common between the third and fifth weeks of infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/20\">",
"       20",
"      </a>",
"      ]. Patients frequently produce mucoid sputum which may contain many eosinophils.",
"     </li>",
"     <li>",
"      Respiratory myositis &mdash; Myositis develops in response to encysted trichinella larvae. The diaphragm may have a relatively high density of encysted larvae compared to other skeletal muscles. Diaphragmatic involvement can result in lower thoracic or epigastric pain and can cause sufficient weakness of the diaphragm to compromise respiratory function [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/27\">",
"       27",
"      </a>",
"      ]. Painful intercostal myositis may further impair respiration [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/35\">",
"       35",
"      </a>",
"      ]. These symptoms occur most frequently in the second and third weeks of infection.",
"      <br/>",
"      <br/>",
"      Symptomatic involvement of the upper airway muscles can also occur. Affected patients may present with hoarseness or dysphagia due to involvement of the laryngeal muscles or the muscles of deglutition.",
"     </li>",
"     <li>",
"      Secondary bacterial pneumonia &mdash; Prolonged bed rest and impaired pulmonary toilet may predispose to secondary bacterial pneumonia in the late stages of severe infection. In one large series of patients hospitalized with trichinellosis, bronchopneumonia occurred in about 1 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37123598\">",
"    <span class=\"h3\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal manifestation of trichinellosis are not common and generally occur only in severe disease. Findings can include proteinuria, hematuria, casts, focal lesions, and renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of trichinellosis should be considered in patients with periorbital edema, myositis, and eosinophilia. Trichinellosis should be particularly suspected in individuals with these symptoms and a history of ingesting either inadequately cooked meat, particularly pork, or a meat source also ingested by other symptomatic individuals.",
"   </p>",
"   <p>",
"    Diagnosis is usually made based on clinical symptoms and is confirmed by serology. Less commonly, muscle biopsy may be used to identify of encysted or non-encysted larvae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Serologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different serologic assays are available, including enzyme-linked immunosorbent assays (ELISA), indirect immunofluorescence, and latex agglutination. Serology is generally reliable; results can be confirmed with a Western blot [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibody levels are not detectable until after three or more weeks of infection so are not useful for early diagnosis. In addition, antibody levels do not correlate with the severity of the clinical course. Antibody tests may remain positive for years after cessation of clinical symptoms. Infection with other helminths and autoimmune diseases can cause false positive serologic test results.",
"   </p>",
"   <p>",
"    Antigen tests have been developed but have relatively poor sensitivity; in one series including 62 patients with confirmed infection, the assay was positive in 47 of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis may be established by identifying larvae on muscle biopsy (",
"    <a class=\"graphic graphic_picture graphicRef56196 \" href=\"UTD.htm?19/44/20165\">",
"     picture 1",
"    </a>",
"    ); this is not generally required but may be useful in the setting of diagnostic uncertainty [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/40\">",
"     40",
"    </a>",
"    ]. The yield of muscle biopsy is highest in symptomatic muscles and near a tendinous insertion. In addition to routine histopathologic examination, the muscle should be examined after enzymatic digestion to free larvae. The specimen can also be examined undigested in a preparation of unfixed muscle compressed between microscope slides (",
"    <a class=\"graphic graphic_picture graphicRef75341 \" href=\"UTD.htm?18/3/18488\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is difficult to differentiate Trichinella species by morphology, but differentiation can be achieved with molecular genetic assays [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H366839361\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction (PCR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multiplex PCR has been developed for the unequivocal differentiation of Trichinella species and genotypes, but it is not commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3986091\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course for most Trichinella infections is uncomplicated and self-limited. For mild infection, antiparasitic therapy is not required; symptomatic treatment with analgesia and antipyretics is appropriate.",
"   </p>",
"   <p>",
"    Management of Trichinella infection with systemic symptoms (including central nervous system manifestations, cardiac inflammation or pulmonary involvement) consists of antiparasitic therapy together with corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/43\">",
"     43",
"    </a>",
"    ]. Antiparasitic therapy is useful for treatment of larvae burrowing into the gastrointestinal tract; a randomized trial including 46 patients with trichinellosis demonstrated that patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    had less myositis and muscle pain than those treated with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the benefits of antiparasitic therapy in the setting of bloodborne larval invasion or encysting of muscle are uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiparasitic for treatment of trichinellosis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (400 mg orally twice daily for 10 to 14 days) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    (200 to 400 mg three times daily for three days, then 400 to 500 mg three times daily for 10 days). Mebendazole is not available in the United States. Data from treatment of patients with echinococcus suggests albendazole levels are more predictable than mebendazole levels [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/14\">",
"     14",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    may be administered concurrently in severe cases at a dose of 30 to 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 10 to 15 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Children and pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplacental transmission of larvae has not been correlated with symptomatic congenital infection, nor have serious intranatal or postnatal newborn infections been described [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    is generally not advisable during pregnancy or in children &le;2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/19,49\">",
"     19,49",
"    </a>",
"    ]. In the setting of intestinal and muscle stages of infection among these patients, anthelminthic treatment is usually not required. However, albendazole or mebendazole has been used in pregnant women with severe infection without adverse fetal effects [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/50\">",
"     50",
"    </a>",
"    ]. In such cases corticosteroid therapy should also be administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28181649\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education regarding consumption of raw domestic and sylvatic animals that can be carriers of Trichinella parasites (if not properly tested for larvae as part of inspection) is an important component of prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15207/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, careful control of farming techniques for pigs (the most important source of Trichinella for humans) with veterinary oversight and use of certified feedstuff are needed.",
"   </p>",
"   <p>",
"    Trichinella larvae in meat may be rendered noninfectious by heating to a temperature of 77&ordm;C. Freezing at -15&ordm;C for three weeks, as in a home freezer, will also generally kill larvae, although arctic species are more resistant to freezing and may remain viable. Irradiation of sealed packed meat also inactivates larvae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27169733\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trichinellosis (trichinosis) is a parasitic infection caused by nematodes (roundworms) of the genus Trichinella. Pigs are the most important source of human infection, although a number of other animals are also epidemiologically important hosts. Consumption of raw or undercooked meat is the principal mode of transmission. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The life cycle consists of two components: a domestic cycle and a sylvatic (",
"      <a class=\"graphic graphic_figure graphicRef51088 \" href=\"UTD.htm?0/52/839\">",
"       figure 1",
"      </a>",
"      ). The domestic cycle usually involves pigs and rodents; other domestic animals, such as horses, can be involved. The sylvatic cycle can involve a broad range of infected animals; animals most frequently implicated as sources of human infection include bear, moose, and wild boar. (See",
"      <a class=\"local\" href=\"#H28181411\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The severity of infection correlates with the number of ingested larvae; mild infection can be subclinical. Heavy infection may have two stages, the intestinal stage (in which larvae mature into adult worms that burrow into the intestinal mucosa) and the muscle stage (in which larvae disseminate hematogenously from the intestines and enter skeletal muscle). Symptoms during the muscle phase include muscle pain, tenderness, weakness, and periorbital edema. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eosinophilia is a hallmark of trichinellosis; it typically develops during the second week of the muscle stage. Nonspecific findings include elevated serum muscle enzymes (creatine kinase and lactate dehydrogenase) and hypergammaglobulinemia. (See",
"      <a class=\"local\" href=\"#H28181701\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious infections may include cardiac, central nervous system,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary involvement. Fatal outcomes in acute trichinellosis usually result from myocarditis, encephalitis, or pneumonia. (See",
"      <a class=\"local\" href=\"#H28181672\">",
"       'Serious infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis is usually based on clinical symptoms and confirmed by serology. Antibody levels are not detectable until after three or more weeks of infection so are not useful for early diagnosis. A definitive diagnosis may be established by identifying larvae on muscle biopsy (",
"      <a class=\"graphic graphic_picture graphicRef56196 \" href=\"UTD.htm?19/44/20165\">",
"       picture 1",
"      </a>",
"      ); this is not generally required, but may be useful in the setting of diagnostic uncertainty. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course for most Trichinella infections is uncomplicated and self-limited. For mild infection, antiparasitic therapy is not required; symptomatic treatment with analgesia and antipyretics is appropriate. Management of Trichinella infection with systemic symptoms (including cardiac inflammation, central nervous system manifestations, or pulmonary involvement) consists of antiparasitic therapy together with corticosteroids. We suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      );",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"       mebendazole",
"      </a>",
"      is an acceptable alternative. Dosing is outlined above. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventive measures include community education, prudent farming techniques, and attention to freezing and cooking techniques to inactivate Trichinella larvae in meat. (See",
"      <a class=\"local\" href=\"#H28181649\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/1\">",
"      Marincu I, Neghina AM, Calma CL, Neghina R. New foci of trichinellosis in western Romania, 2011. Acta Trop 2012; 121:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/2\">",
"      Murrell KD, Bruschi F. Clinical trichinellosis. Prog Clin Parasitol 1994; 4:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/3\">",
"      Murrell KD, Pozio E. Trichinellosis: the zoonosis that won't go quietly. Int J Parasitol 2000; 30:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/4\">",
"      Ranque S, Faug&egrave;re B, Pozio E, et al. Trichinella pseudospiralis outbreak in France. Emerg Infect Dis 2000; 6:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/5\">",
"      Jongwutiwes S, Chantachum N, Kraivichian P, et al. First outbreak of human trichinellosis caused by Trichinella pseudospiralis. Clin Infect Dis 1998; 26:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/6\">",
"      Pozio E, La Rosa G. Trichinella murrelli n. sp: etiological agent of sylvatic trichinellosis in temperate areas of North America. J Parasitol 2000; 86:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/7\">",
"      Pozio E, Owen IL, La Rosa G, et al. Trichinella papuae n.sp. (Nematoda), a new non-encapsulated species from domestic and sylvatic swine of Papua New Guinea. Int J Parasitol 1999; 29:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/8\">",
"      Khumjui C, Choomkasien P, Dekumyoy P, et al. Outbreak of trichinellosis caused by Trichinella papuae, Thailand, 2006. Emerg Infect Dis 2008; 14:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/9\">",
"      Kusolsuk T, Kamonrattanakun S, Wesanonthawech A, et al. The second outbreak of trichinellosis caused by Trichinella papuae in Thailand. Trans R Soc Trop Med Hyg 2010; 104:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/10\">",
"      Lo YC, Hung CC, Lai CS, et al. Human trichinosis after consumption of soft-shelled turtles, Taiwan. Emerg Infect Dis 2009; 15:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/11\">",
"      Pozio E. Foodborne and waterborne parasites. Acta Microbiol Pol 2003; 52 Suppl:83.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.iss.it/site/Trichinella/index.asp (Accessed on November 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/13\">",
"      Ancelle T, Dupouy-Camet J, Desenclos JC, et al. A multifocal outbreak of trichinellosis linked to horse meat imported from North America to France in 1993. Am J Trop Med Hyg 1998; 59:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/14\">",
"      Gottstein B, Pozio E, N&ouml;ckler K. Epidemiology, diagnosis, treatment, and control of trichinellosis. Clin Microbiol Rev 2009; 22:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/15\">",
"      Kennedy ED, Hall RL, Montgomery SP, et al. Trichinellosis surveillance - United States, 2002-2007. MMWR Surveill Summ 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Trichinellosis associated with bear meat--New York and Tennessee, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/17\">",
"      Roy SL, Lopez AS, Schantz PM. Trichinellosis surveillance--United States, 1997-2001. MMWR Surveill Summ 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/18\">",
"      Moorhead A, Grunenwald PE, Dietz VJ, Schantz PM. Trichinellosis in the United States, 1991-1996: declining but not gone. Am J Trop Med Hyg 1999; 60:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/19\">",
"      Kociecka W. Trichinellosis: human disease, diagnosis and treatment. Vet Parasitol 2000; 93:365.",
"     </a>",
"    </li>",
"    <li>",
"     Gould SE. Clinical manifestations. In: Trichinosis in Man and Animals, Gould SE (Ed), Charles C Thomas, Springfield, IL 1970. p.269.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/21\">",
"      MacLean JD, Poirier L, Gyorkos TW, et al. Epidemiologic and serologic definition of primary and secondary trichinosis in the Arctic. J Infect Dis 1992; 165:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/22\">",
"      Neghina R, Neghina AM. Reviews on trichinellosis (IV): hepatic involvement. Foodborne Pathog Dis 2011; 8:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/23\">",
"      Akar S, Gurler O, Pozio E, et al. Frequency and severity of musculoskeletal symptoms in humans during an outbreak of trichinellosis caused by Trichinella britovi. J Parasitol 2007; 93:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/24\">",
"      Pozio E. New patterns of Trichinella infection. Vet Parasitol 2001; 98:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/25\">",
"      Andrews JR, Ainsworth R, Abernethy D. Trichinella pseudospiralis in humans: description of a case and its treatment. Trans R Soc Trop Med Hyg 1994; 88:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/26\">",
"      Lazarevi�� AM, Neskovi�� AN, Goronja M, et al. Low incidence of cardiac abnormalities in treated trichinosis: a prospective study of 62 patients from a single-source outbreak. Am J Med 1999; 107:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/27\">",
"      Compton SJ, Celum CL, Lee C, et al. Trichinosis with ventilatory failure and persistent myocarditis. Clin Infect Dis 1993; 16:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/28\">",
"      Neghina R, Neghina AM, Marincu I. Reviews on trichinellosis (III): cardiovascular involvement. Foodborne Pathog Dis 2011; 8:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/29\">",
"      Fourestie V, Douceron H, Brugieres P, et al. Neurotrichinosis. A cerebrovascular disease associated with myocardial injury and hypereosinophilia. Brain 1993; 116 ( Pt 3):603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/30\">",
"      Puljiz I, Beus A, Kuzman I, Seiwerth S. Electrocardiographic changes and myocarditis in trichinellosis: a retrospective study of 154 patients. Ann Trop Med Parasitol 2005; 99:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/31\">",
"      Mawhorter SD, Kazura JW. Trichinosis of the central nervous system. Semin Neurol 1993; 13:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/32\">",
"      Gelal F, Kumral E, Vidinli BD, et al. Diffusion-weighted and conventional MR imaging in neurotrichinosis. Acta Radiol 2005; 46:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/33\">",
"      Neghina R, Neghina AM, Marincu I, Iacobiciu I. Reviews on trichinellosis (II): neurological involvement. Foodborne Pathog Dis 2011; 8:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/34\">",
"      Januszkiewicz, J. Participation of the respiratory system in trichinosis. Epidemiol Rev 1967; 21:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/35\">",
"      ROBIN ED, CRUMP CH, WAGMAN RJ. Low sedimentation rate, hypofibrinogenemia and restrictive pseudo-obstructive pulmonary disease associated with trichinosis. N Engl J Med 1960; 262:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/36\">",
"      Neghina R, Neghina AM, Marincu I, Iacobiciu I. Reviews on trichinellosis (I): renal involvement. Foodborne Pathog Dis 2011; 8:179.",
"     </a>",
"    </li>",
"    <li>",
"     Murrell KD, Bruschi F. Clinical trichinellosis. In: Progress in clinical parasitology, Sun T (Ed), CRC Press, Boca Raton 1994. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/38\">",
"      Moskwa B, Bien J, Cabaj W, et al. The comparison of different ELISA procedures in detecting anti-Trichinella IgG in human infections. Vet Parasitol 2009; 159:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/39\">",
"      Ivanoska D, Cuperlovi�� K, Gamble HR, Murrell KD. Comparative efficacy of antigen and antibody detection tests for human trichinellosis. J Parasitol 1989; 75:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/40\">",
"      Bruschi F, Murrell KD. New aspects of human trichinellosis: the impact of new Trichinella species. Postgrad Med J 2002; 78:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/41\">",
"      Rombout YB, Bosch S, Van Der Giessen JW. Detection and identification of eight Trichinella genotypes by reverse line blot hybridization. J Clin Microbiol 2001; 39:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/42\">",
"      Zarlenga DS, Chute MB, Martin A, Kapel CM. A single, multiplex PCR for differentiating all species of Trichinella. Parasite 2001; 8:S24.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections. Medical Lett Drugs Ther. 0nline. file://www.medicalletter.org/parasitic (Accessed on November 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/44\">",
"      Watt G, Saisorn S, Jongsakul K, et al. Blinded, placebo-controlled trial of antiparasitic drugs for trichinosis myositis. J Infect Dis 2000; 182:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/45\">",
"      Pozio E, Sacchini D, Sacchi L, et al. Failure of mebendazole in the treatment of humans with Trichinella spiralis infection at the stage of encapsulating larvae. Clin Infect Dis 2001; 32:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/46\">",
"      Nu&ntilde;ez GG, Costantino SN, Gentile T, Venturiello SM. Immunoparasitological evaluation of Trichinella spiralis infection during human pregnancy: a small case series. Trans R Soc Trop Med Hyg 2008; 102:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/47\">",
"      Dubinsk&yacute; P, B&ouml;&ouml;r A, Kincekov&aacute; J, et al. Congenital trichinellosis? Case report. Parasite 2001; 8:S180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/48\">",
"      Nu&ntilde;ez GG, Gentile T, Calcagno ML, Venturiello SM. Increased parasiticide activity against Trichinella spiralis newborn larvae during pregnancy. Parasitol Res 2002; 88:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/49\">",
"      Dupouy-Camet J, Kociecka W, Bruschi F, et al. Opinion on the diagnosis and treatment of human trichinellosis. Expert Opin Pharmacother 2002; 3:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15207/abstract/50\">",
"      Gyorkos TW, Larocque R, Casapia M, Gotuzzo E. Lack of risk of adverse birth outcomes after deworming in pregnant women. Pediatr Infect Dis J 2006; 25:791.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5719 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15207=[""].join("\n");
var outline_f14_54_15207=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27169733\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28181411\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28181427\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28181732\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28181701\">",
"      - Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28181672\">",
"      Serious infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Neurologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37123598\">",
"      - Renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Serologic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H366839361\">",
"      Polymerase chain reaction (PCR)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3986091\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Children and pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28181649\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27169733\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5719\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5719|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/52/839\" title=\"figure 1\">",
"      Trichinellosis life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5719|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/44/20165\" title=\"picture 1\">",
"      Encysted Trichinella larvae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/30/25056\" title=\"picture 2\">",
"      Splinter hemorrhage trichinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/3/18488\" title=\"picture 3\">",
"      Trichinella larvae in muscle",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=related_link\">",
"      Muscle enzymes in the evaluation of neuromuscular diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_54_15208="Splinting of musculoskeletal injuries";
var content_f14_54_15208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Splinting of musculoskeletal injuries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/54/15208/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15208/contributors\">",
"     Rana Kronfol, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/54/15208/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15208/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15208/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15208/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/54/15208/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15208/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/54/15208/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splinting plays a major role in the management of musculoskeletal injuries, particularly those involving extremity fractures and joint dislocations. Immobilization of the extremity through splinting decreases pain and bleeding and prevents further soft tissue, vascular, or neurologic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Splinting may provide definitive treatment for some injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with casts, splints permit swelling and may prevent neurovascular compromise. The clinician should perform splinting immediately after the injury and maintain splinting or casting until the injury has healed completely.",
"   </p>",
"   <p>",
"    The basic principles, method of application, and description of specific splints for the upper and lower extremities will be discussed here. Closed reduction and casting for distal forearm fractures in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link\">",
"     \"Closed reduction and casting of distal forearm fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splints have traditionally been made of plaster of Paris, but in recent years many different types of splinting materials have become widely available. These include pre-formed plaster, fiberglass, pre-padded fiberglass, malleable aluminium, air splints, vacuum splints, and pre-formed \"off-the-shelf\" splints for nearly every body part.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H576000\">",
"    <span class=\"h2\">",
"     Preformed splints",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice between pre-formed splints and custom splints is largely one of convenience and compliance. Commercial pre-formed splints are typically made of Velcro and hard plastic. They are very convenient and come in a variety of sizes to fit most patients. However, since these splints are not custom-molded, they do not provide the same level of immobilization as custom built splints. Additionally, patients can easily remove commercial splints, potentially causing delayed healing, fracture displacement, or re-injury. Hence, custom splinting with plaster, fiberglass or similar materials may be preferred when precise and continuous immobilization is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H576007\">",
"    <span class=\"h2\">",
"     Manufactured splints",
"    </span>",
"    &nbsp;&mdash;&nbsp;The equipment necessary for the application of a manufactured splint includes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cotton bandage (eg, Webril&reg;) for padding",
"     </li>",
"     <li>",
"      Plaster slabs or rolls or pre-padded fiberglass splint material (eg, OCL&reg; and Orthoglass&reg;) of various widths (2, 3, 4, and 6 inches [5, 7.5, 10, and 15 cm])",
"     </li>",
"     <li>",
"      Room temperature water",
"     </li>",
"     <li>",
"      Elastic bandage (eg, Ace&reg; bandage)",
"     </li>",
"     <li>",
"      Adhesive tape",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most splints are made from plaster or fiberglass. Plaster splints are made from gauze that is impregnated with plaster of Paris, a powdered form of gypsum. When water is added, the gypsum recrystallizes and hardens in a heat-releasing reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/3\">",
"     3",
"    </a>",
"    ]. To minimize the risk of burns, use water that is no warmer than room temperature. Plaster splints take between two and eight minutes to set, but they do not reach their maximum strength for approximately 24 hours. Plaster splints are easier to mold and are less expensive than fiberglass splints. However, they are more difficult to apply and become soggy when wet [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fiberglass and other synthetic splints (eg, Orthoglass&reg;, OCL&reg;, and Velcro splints) usually are pre-padded and easier to apply. In addition, synthetic splints set more quickly and are lighter, longer-wearing, and water-resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/3-5,11\">",
"     3-5,11",
"    </a>",
"    ]. However, they are more expensive and do not mold as well as plaster splints.",
"   </p>",
"   <p>",
"    More sophisticated prefabricated splints, consisting of plastic shells lined with air cells, foam, or gel components, are widely available and have the same advantages and disadvantages as fiberglass splints [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Air splints (also called air casts) provide less support than plaster or fiberglass splints (",
"    <a class=\"graphic graphic_picture graphicRef78043 \" href=\"UTD.htm?14/23/14706\">",
"     picture 1",
"    </a>",
"    ). They tend to be used for ankle sprains and stress fractures rather than fractures because they prevent",
"    <span class=\"nowrap\">",
"     eversion/inversion",
"    </span>",
"    injury while permitting free",
"    <span class=\"nowrap\">",
"     flexion/extension.",
"    </span>",
"    Furthermore, the amount of air in the splint can be increased as swelling resolves in order to maintain support during healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BASIC PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advise field personnel to splint injuries suspected to be fractures before the patient is transported for medical evaluation. Commercial splinting devices are available and easy to use. If commercial devices are unavailable field personnel can manufacture splints from cardboard, magazines, or other malleable, semi-rigid material [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following basic principles apply to splinting applied by medical personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/1-6,11,13\">",
"     1-6,11,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide pain control, as needed, prior to splinting.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      provides reasonable pain control for many injuries. Patients with significant pain warrant parenteral opioids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/15/44280?source=see_link&amp;anchor=H12#H12\">",
"       \"Evaluation and management of pain in children\", section on 'Pharmacologic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assess the full extent of the injury and obtain adequate exposure for splint application. Obtain emergent orthopedic surgery evaluation for open, angulated, or displaced fractures; dislocations that cannot be reduced; and patients with neurovascular compromise.",
"     </li>",
"     <li>",
"      Expose the extremity completely before the splint is applied. Clean, repair, and dress skin lesions before applying the splint.",
"     </li>",
"     <li>",
"      Take into account the patient's ability to remove his or her clothing with the splint in place before applying the splint.",
"     </li>",
"     <li>",
"      Ensure adequate and comfortable immobilization:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Make sure that splints are of appropriate size, weight, and shape. Make the plaster or fiberglass slab wide enough to cover approximately one-half of the circumference of the extremity in children; do not allow the edges to overlap. For adults, use 2 inch splinting material for finger splints; 3 and 4 inch widths for upper extremity splints; and 5 to 6 inch widths for lower extremity splinting.",
"     </li>",
"     <li>",
"      Prevention of skin breakdown by the use of proper padding is vitally important. Pad the heels, elbows, and all bony prominences adequately; place padding between the digits to prevent maceration; place extra padding over the fracture site.",
"     </li>",
"     <li>",
"      Immobilize the joints above and below a fracture unless this is not possible (such as for distal fractures below the elbow or knee).",
"     </li>",
"     <li>",
"      Immobilize the bones above and below a dislocated joint unless this is not possible (such as for distal fractures below the elbow or knee).",
"     </li>",
"     <li>",
"      To prevent stiffness and loss of function, splint the involved joints in their positions of function (",
"      <a class=\"graphic graphic_table graphicRef51226 \" href=\"UTD.htm?20/47/21243\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/3\">",
"       3",
"      </a>",
"      ]. In the hand, to achieve the position of safety, which differs from the position of function, extend the wrist 20 degrees, flex the metacarpophalangeal joints 90 degrees, and fully extend the proximal and distal interphalangeal joints (",
"      <a class=\"graphic graphic_figure graphicRef60552 \" href=\"UTD.htm?34/24/35200\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Never splint fractures circumferentially, particularly if the patient has impaired sensation, excessive swelling, or circulatory insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/3-5,7,13\">",
"       3-5,7,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Evaluate neurovascular status before and after application of the splint.",
"     </li>",
"     <li>",
"      Provide slings for added support or crutches to prevent weightbearing or use of the extremity. These activities may increase pain or swelling",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cause the splint to break [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/11\">",
"       11",
"      </a>",
"      ]. Most children can learn to use crutches by the time they are six to seven years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide aftercare instructions and ensure adequate follow-up:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Instruct the patient to return to the physician for evaluation of any numbness, tingling, or increased pain in the area underneath or distal to the splint.",
"     </li>",
"     <li>",
"      To minimize swelling, ask the patient to keep the extremity elevated, iced, and rested until reevaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/3-7,13\">",
"       3-7,13",
"      </a>",
"      ]. Ice is effective through the layers of Webril&reg; and Ace&reg; wrap in an area that is not covered with",
"      <span class=\"nowrap\">",
"       plaster/fiberglass.",
"      </span>",
"      To ice the splinted extremity, place a bag of ice (or frozen vegetables) on the outside of the splint for 20 minutes. A longer duration may numb the extremity, and a shorter one may not markedly affect swelling. Place a layer of cloth or towel under the ice if the bag is too cold.",
"     </li>",
"     <li>",
"      Check splints 24 to 48 hours after application to ensure adequate fit and neurovascular integrity, evaluating for the five Ps (",
"      <strong>",
"       p",
"      </strong>",
"      allor,",
"      <strong>",
"       p",
"      </strong>",
"      ain,",
"      <strong>",
"       p",
"      </strong>",
"      aresthesia,",
"      <strong>",
"       p",
"      </strong>",
"      ulselessness, and",
"      <strong>",
"       p",
"      </strong>",
"      aralysis).",
"     </li>",
"     <li>",
"      Make sure that there is another evaluation, usually performed by an orthopedist, 7 to 10 days after injury. By this time, swelling usually has resolved and a cast can be applied if one is indicated. A cast provides longer lasting support and immobilization for the treatment of fractures. Initiate physical therapy (if indicated) after splinting to prevent \"freezing\" or contracture of the joints.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF SPLINTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;When splints are applied correctly, complications rarely occur. Complications include sores, abrasions, and possible infections from loose or ill-fitting splints; neurovascular compromise from tight-fitting splints; contact dermatitis; pressure sores; and thermal burns (from heat released during setting of plaster) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/1,2,11,12,15\">",
"     1,2,11,12,15",
"    </a>",
"    ]. Most of these complications can be avoided through careful application of the splint and monitoring of the patient's neurovascular status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SPLINT APPLICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of splint varies depending upon the site of the injury. The most basic splint is composed of a layer of stockinette, with or without padding, and several layers of plaster (or pre-padded fiberglass) that are molded to provide comfort, support, and immobilization (",
"    <a class=\"graphic graphic_picture graphicRef59847 \" href=\"UTD.htm?29/1/29718\">",
"     picture 2",
"    </a>",
"    ). Wrap additional padding for bulk and a final layer of cotton or elastic bandage around the plaster or fiberglass to hold everything in place [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/1,3-7,12\">",
"     1,3-7,12",
"    </a>",
"    ]. Do not wrap the final layer too tightly. Secure the bandage with tape rather than pins to prevent injuries from pins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Customized plaster splints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Customized plaster splints may be manufactured to remain in place or to be removable.",
"   </p>",
"   <p>",
"    The application of plaster splints designed to remain in place requires the following steps [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the optional stockinette is to be used, stretch and smooth it over the extremity; extend the stockinette beyond the proximal and distal edges of the area to be splinted.",
"     </li>",
"     <li>",
"      Wrap cotton bandage (eg, Webril&reg;) around the extremity in a distal to proximal fashion; overlap each turn to cover the previous one by 50 percent. Be careful to avoid wrinkles because they can create pressure points. Extend the padding 2 to 3 cm beyond the area to be splinted. If stockinette has been used, extend it beyond the proximal and distal edges of the cotton bandage.",
"     </li>",
"     <li>",
"      Measure the plaster strips and cut to length. Cut the strips slightly longer than necessary so they can be folded back on themselves to create a smooth edge and to allow for contraction of the plaster as it crystallizes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/11\">",
"       11",
"      </a>",
"      ]. Use approximately 8 to 10 layers for an upper extremity splint and 12 to 14 layers for a lower extremity splint. The risk of thermal injury is directly related to the number of plaster layers and the adequacy of padding.",
"     </li>",
"     <li>",
"      Immerse the plaster in water at room-temperature and then place it on an open towel to remove excess water and smooth the plaster.",
"     </li>",
"     <li>",
"      Apply the plaster to the extremity, molding it to the extremity",
"     </li>",
"     <li>",
"      Before the plaster hardens, fold back the proximal and distal ends over themselves to form a smooth edge; if stockinette was used, fold it over the edge of the plaster.",
"     </li>",
"     <li>",
"      Apply an (optional) layer of cast padding over the splint to prevent the plaster from sticking to the elastic bandage of the final layer or apply the elastic bandage directly to the splint.",
"     </li>",
"     <li>",
"      Wrap an elastic bandage (Ace&reg; wrap) around the extremity, distal to proximal, to secure the plaster to the extremity. Keep the limb in the desired position until the plaster hardens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Removable plaster splints are manufactured as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cut a piece of stockinette slightly longer than the desired length of the splint.",
"     </li>",
"     <li>",
"      Measure the plaster strips and cut or fold to length. Use approximately 8 to 10 layers for an upper extremity splint and 12 to 14 layers for a lower extremity splint.",
"     </li>",
"     <li>",
"      Tear two pieces of cast padding (eg, Webril&trade;) slightly longer and wider than the plaster strips.",
"     </li>",
"     <li>",
"      Immerse the plaster in water at room-temperature and then place it on an open towel to remove excess water and smooth the plaster.",
"     </li>",
"     <li>",
"      Place the plaster between the two strips of cast padding and place inside the stockinette (",
"      <a class=\"graphic graphic_picture graphicRef59847 \" href=\"UTD.htm?29/1/29718\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Apply the removable plaster splint to the desired area and secure with an elastic bandage as described above.",
"     </li>",
"     <li>",
"      After the plaster has hardened, rewrap the elastic bandage to provide snug but not constrictive tension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fiberglass splints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow the manufacturer's instructions for application when using prefabricated splints [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/11\">",
"     11",
"    </a>",
"    ]. Before proceeding, assess the patient for a history of hypersensitivity to fiberglass.",
"   </p>",
"   <p>",
"    The following steps typically are included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the optional stockinette is to be used, stretch and smooth it over the extremity; extend the stockinette beyond the proximal and distal edges of the area to be splinted.",
"     </li>",
"     <li>",
"      Cut the fiberglass splint to the proper length (eg, slightly longer than necessary so it can be folded back on itself to create a smooth edge).",
"     </li>",
"     <li>",
"      Immerse the fiberglass splint in room-temperature water and then place it on an open towel and roll it up inside the towel to remove excess water.",
"     </li>",
"     <li>",
"      Apply the fiberglass splint to the extremity and mold it to the desired shape; stretch the padding material over the proximal and distal edges of the splint to prevent sharp edges.",
"     </li>",
"     <li>",
"      Apply an elastic bandage to provide snug but not constrictive tension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     UPPER EXTREMITY SPLINTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The style of splint varies depending upon the injury (",
"    <a class=\"graphic graphic_table graphicRef55110 \" href=\"UTD.htm?12/35/12860\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sling and swathe splint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use the sling and swathe splint primarily for shoulder and humeral injuries. The sling supports the weight of the arm and the swathe holds the arm against the chest to minimize shoulder motion. Commercial models are available, but a simple sling with a 6 inch elastic bandage will do. Place a powdered pad in the axilla before the splint is applied to prevent maceration (",
"    <a class=\"graphic graphic_figure graphicRef78370 \" href=\"UTD.htm?26/7/26736\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Velpeau bandage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Velpeau bandage is another splint that is used for shoulder and humeral injuries. It is similar to the sling and swathe splint, except that the hand is held higher and the forearm lies against the chest (",
"    <a class=\"graphic graphic_figure graphicRef65610 \" href=\"UTD.htm?10/12/10436\">",
"     figure 3",
"    </a>",
"    ). The decision to use the sling and swathe splint or the Velpeau bandage is based upon the patient's comfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sugar tong splints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use the sugar tong splint to treat humeral shaft, forearm, and wrist fractures and apply according to the area involved.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use the proximal sugar tong splint for humeral fractures. Apply the plaster from the axilla around the elbow and up the arm on the other side to the level of the axilla (",
"      <a class=\"graphic graphic_figure graphicRef69310 \" href=\"UTD.htm?5/12/5315\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Use the distal sugar tong splint, also called the forearm sugar tong splint, for wrist and distal forearm fractures. It extends from the metacarpophalangeal joints on the dorsum of the hand along the forearm, wrapping around the elbow back to the volar aspect of the midpalmar crease (",
"      <a class=\"graphic graphic_figure graphicRef50501 \" href=\"UTD.htm?36/26/37281\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/5\">",
"       5",
"      </a>",
"      ]. The distal sugar tong splint immobilizes the elbow, forearm, and wrist. Assess finger motion to prevent finger stiffness.",
"     </li>",
"     <li>",
"      Use the double sugar tong splint for elbow and forearm fractures because it limits",
"      <span class=\"nowrap\">",
"       flexion/extension",
"      </span>",
"      at the elbow as well as",
"      <span class=\"nowrap\">",
"       pronation/supination.",
"      </span>",
"      It is a combination of the proximal and distal sugar tong splints.",
"     </li>",
"     <li>",
"      Use the reverse sugar tong splint for forearm and Colles fractures because it provides good distal support and better dorsal and ventral support than the Colles or volar splints. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Colles splint'",
"      </a>",
"      below.) The reverse sugar tong splint wraps around the hand and between the thumb and fingers instead of around the elbow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Long arm splint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use the long arm splint (or posterior splint) for stable injuries of the elbow area or forearm. Use it also to temporarily stabilize intraarticular fractures of the humerus, olecranon, or radial head in patients awaiting surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long arm splint is a long posterior splint from above the elbow to the midpalmar crease. Apply it posteriorly to the arm, elbow, and forearm up to the wrist, with the elbow flexed at a 90 degree angle (",
"    <a class=\"graphic graphic_figure graphicRef70004 \" href=\"UTD.htm?23/24/23951\">",
"     figure 6",
"    </a>",
"    ). Apply extra strips of plaster across the joint for further reinforcement. Because the long arm splint permits pronation and supination, do not use it for complex or unstable distal forearm fractures. Double sugar-tong splints are better for these injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Colles splint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use the Colles splint to provide volar support (",
"    <a class=\"graphic graphic_figure graphicRef56747 \" href=\"UTD.htm?15/62/16352\">",
"     figure 7",
"    </a>",
"    ). Use it for fractures of the second to fifth metacarpals and distal forearm and wrist fractures as an alternative to the distal or reverse sugar tong splints. The reverse sugar tong splint offers more dorsal and ventral support and is used more often in younger children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dorsal and/or volar splint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use the dorsal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    volar short arm splint for carpal tunnel syndrome, soft tissue injuries of the hand, and fractures or injuries of the wrist. Apply it from the midpalmar crease almost to the elbow, dorsally",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventrally (",
"    <a class=\"graphic graphic_figure graphicRef65696 \" href=\"UTD.htm?42/15/43263\">",
"     figure 8",
"    </a>",
"    ). The use of dorsal and ventral splints in combination provides increased stability. Use the dorsal and ventral splints in combination to provide increased stability. Do not use this splint for distal forearm fractures because it permits",
"    <span class=\"nowrap\">",
"     pronation/supination.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44008?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of carpal tunnel syndrome\", section on 'Wrist splinting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gutter splint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use gutter splints primarily for phalangeal and metacarpal fractures. These splints extend from the proximal forearm to beyond the distal interphalangeal joint and can be radial (immobilizing the index and long fingers) or ulnar (immobilizing the ring and little fingers, also called the boxer splint). Make sure that the splint is wide enough to surround both fingers and the wrist. Cut the radial gutter splint before application, creating a hole through which the thumb can pass.",
"   </p>",
"   <p>",
"    In order to avoid finger stiffness, splint the fingers with the metacarpophalangeal joints in 70 degrees flexion, the proximal interphalangeal joint (PIP) in 20 to 30 degrees of flexion, and the distal interphalangeal joint (DIP) in no more than 5 to 10 degrees of flexion (",
"    <a class=\"graphic graphic_figure graphicRef59409 \" href=\"UTD.htm?10/0/10240\">",
"     figure 9",
"    </a>",
"    ). Place wadding between the fingers before application of the splint so as to prevent skin irritation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Thumb spica splint",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thumb spica splint is a variation on the gutter splint. Use it for scaphoid fractures and extra-articular fractures of the thumb metacarpal or ulnar collateral ligament injuries (ie, gamekeeper's thumb or skier's thumb) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]. Place the splint on the radial aspect of the forearm, wrapping the thumb up to the distal interphalangeal joint (",
"    <a class=\"graphic graphic_figure graphicRef79534 \" href=\"UTD.htm?26/19/26943\">",
"     figure 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32068?source=see_link\">",
"     \"Ulnar collateral ligament injury (gamekeeper's or skier's thumb)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Finger splints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splinting varies according to the type of finger injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A transverse, oblique, or avulsion fracture of the proximal phalanx that is nondisplaced, is not angulated, and appears stable can be treated by buddy taping the injured finger to an adjacent finger. If the ring finger is involved, it should be buddy taped to the little finger (",
"      <a class=\"graphic graphic_picture graphicRef79535 \" href=\"UTD.htm?21/8/21635\">",
"       picture 3",
"      </a>",
"      ). Alternatively, if there is significant pain or swelling, a splint such as a gutter (",
"      <a class=\"graphic graphic_figure graphicRef59409 \" href=\"UTD.htm?10/0/10240\">",
"       figure 9",
"      </a>",
"      ) or Burkhalter (",
"      <a class=\"graphic graphic_picture graphicRef77846 \" href=\"UTD.htm?7/0/7183\">",
"       picture 4",
"      </a>",
"      ) may be used for increased comfort and stability. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20037?source=see_link\">",
"       \"Proximal phalanx fractures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nondisplaced stable fractures of the middle phalanx without angulation are treated by buddy taping them to an adjacent finger (",
"      <a class=\"graphic graphic_picture graphicRef79535 \" href=\"UTD.htm?21/8/21635\">",
"       picture 3",
"      </a>",
"      ). If the ring finger is involved, it should be buddy taped to the little finger. Short-term immobilization with a dorsal (",
"      <a class=\"graphic graphic_picture graphicRef53670 \" href=\"UTD.htm?37/10/38063\">",
"       picture 5",
"      </a>",
"      ) or volar finger splint (",
"      <a class=\"graphic graphic_picture graphicRef76059 \" href=\"UTD.htm?31/41/32415\">",
"       picture 6",
"      </a>",
"      ) or a toad splint (",
"      <a class=\"graphic graphic_picture graphicRef65838 \" href=\"UTD.htm?12/0/12288\">",
"       picture 7",
"      </a>",
"      ) can be used for added protection or pain control (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40885?source=see_link\">",
"       \"Middle phalanx fractures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nondisplaced distal phalanx fractures should be splinted with the DIP joint in extension. The splint should extend past the tip of the distal phalanx to protect it from injury (",
"      <a class=\"graphic graphic_picture graphicRef56147 \" href=\"UTD.htm?24/58/25519\">",
"       picture 8",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link\">",
"       \"Distal phalanx fractures\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immobilization of digit dislocations, jersey finger, and mallet deformity is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16216?source=see_link\">",
"     \"Digit dislocation reduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28581?source=see_link\">",
"     \"Flexor tendon injury of the distal interphalangeal joint (jersey finger)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=see_link\">",
"     \"Extensor tendon injury of the distal interphalangeal joint (mallet finger)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bulky hand compression dressing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use a bulky hand compression dressing for closed hand fractures. This dressing provides bulky compression and minimizes edema. Wrap Kerlix gauze around the hand after cotton fluffs are placed between the fingers. Add a dorsal or volar splint for wrist immobilization. Wrap an elastic bandage around the hand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3998419\">",
"    <span class=\"h2\">",
"     Figure-of-eight splint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a simple sling is often used for clavicle fractures, the figure-of-eight splint may be useful in selected fractures of the middle two-thirds of the clavicle. Apply this splint while the patient is erect, with the hands on the iliac crests and the shoulders held in abduction. Wrap a stockinette or padding snugly around both shoulders (",
"    <a class=\"graphic graphic_figure graphicRef61881 \" href=\"UTD.htm?20/33/21008\">",
"     figure 11",
"    </a>",
"    ). A premade version of this splint is available.",
"   </p>",
"   <p>",
"    Initial nonoperative treatment of fractures of the middle third of the clavicle is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12985?source=see_link&amp;anchor=H10#H10\">",
"     \"Clavicle fractures\", section on 'Initial nonoperative treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LOWER EXTREMITY SPLINTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The style of splint varies depending upon the injury (",
"    <a class=\"graphic graphic_table graphicRef53065 \" href=\"UTD.htm?13/14/13547\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Knee splint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ready-made splints are available and usually used for knee injuries and proximal fractures of the tibia and fibula. Reserve the splint described here for patients who are too large for ready-made splints. With the knee placed in full extension, extend 6 inch plaster rolls from the buttocks posteriorly to 3 inches (7.5 cm) above the malleoli (",
"    <a class=\"graphic graphic_figure graphicRef59184 \" href=\"UTD.htm?17/16/17678\">",
"     figure 12",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Jones compression dressing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use the Jones compression dressing splint for knee and calf injuries. Wrap the entire leg in wadding, then cotton padding followed by elastic wrap. Apply plaster splints to the medial, lateral, and posterior aspect of the knee.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Posterior leg splint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use the posterior leg (or ankle) splint for distal leg, ankle, tarsal, and metatarsal fractures, reduced dislocations, and severe sprains. Place a plaster splint from the metatarsal heads to the fibular neck (",
"    <a class=\"graphic graphic_figure graphicRef63670 \" href=\"UTD.htm?36/6/36960\">",
"     figure 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55706 \" href=\"UTD.htm?22/2/22565\">",
"     picture 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/5\">",
"     5",
"    </a>",
"    ]. Keep the fibular neck and head free to avoid compression of the peroneal nerves. Provide crutches for patients with this type of splint (if they are able to use them), because the splint is not strong enough at the ankle to permit weightbearing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/6\">",
"     6",
"    </a>",
"    ]. Use the posterior leg splint in combination with the stirrup splint to increase stability; the posterior splint should be applied first [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Stirrup splint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apply the ankle stirrup splint, also called the ankle sugar tong splint, to prevent inversion or eversion of the ankle, and provide better immobilization that the posterior leg splint for fractures near the ankle. Use it in combination with the posterior leg splint, which should be placed first [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/11\">",
"     11",
"    </a>",
"    ]. The stirrup splint is similar to the sugar tong splints described above, in which plaster is applied from below the knee and wrapped around the ankle (",
"    <a class=\"graphic graphic_figure graphicRef72529 \" href=\"UTD.htm?28/33/29200\">",
"     figure 14",
"    </a>",
"    ). Facilitate application by having the patient lie in the prone position with the knee flexed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients with stirrup splints can bear weight 36 hours after the splint is applied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Bulky foot compression dressing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bulky foot compression splint is similar to the hand compression. Use it to treat calcaneal fractures and foot injuries. Place cotton fluffs between the toes, apply sheet wadding in several layers and wrap the foot with elastic bandage (",
"    <a class=\"graphic graphic_picture graphicRef55324 \" href=\"UTD.htm?35/10/36015\">",
"     picture 10",
"    </a>",
"    ). Make sure the elastic wrap is looser around the leg than the ankle, to provide a pressure gradient and facilitate drainage for edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Buddy taping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use buddy taping for phalangeal fractures of the toes. Place a small sheet of wadding between the toes to prevent maceration, and secure the fractured toe to the adjacent toe with adhesive strips (",
"    <a class=\"graphic graphic_figure graphicRef74291 \" href=\"UTD.htm?41/25/42397\">",
"     figure 15",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28207296\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An instructional video on basic splinting techniques is available elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15208/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=see_link\">",
"       \"Patient information: Common wrist injuries (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17439119\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splinting plays a major role in the management of musculoskeletal injuries, particularly those involving extremity fractures and joint dislocations. Immobilization of the extremity through splinting decreases pain and bleeding and prevents further soft tissue, vascular, or neurologic compromise. Splinting may provide definitive treatment for some injuries. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to splint application, the clinician should assess for neurovascular compromise and other findings that indicate the need for prompt referral to an orthopedic surgeon (eg, displaced fracture, open fracture). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Basic principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Splints should typically maintain joints in the position of function, or for finger splints, the position of safety (",
"      <a class=\"graphic graphic_table graphicRef51226 \" href=\"UTD.htm?20/47/21243\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef60552 \" href=\"UTD.htm?34/24/35200\">",
"       figure 1",
"      </a>",
"      ). For most fractures, the splint should immobilize the joint above and the joint below the fractured bone. For most dislocations, the splint should immobilize the bone above and the bone below the reduced joint. Proper padding, correct sizing of splint materials, and reassessment of neurovascular status are important to prevent complications from splinting. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Basic principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tables provide potential indications for specific upper and lower extremity splints (",
"      <a class=\"graphic graphic_table graphicRef55110 \" href=\"UTD.htm?12/35/12860\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53065 \" href=\"UTD.htm?13/14/13547\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Upper extremity splints'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Lower extremity splints'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plaster splints are made from gauze that is impregnated with plaster of Paris, a powdered form of gypsum. When water is added, the gypsum recrystallizes and hardens in a heat-releasing reaction. To minimize the risk of burns, use water that is no warmer than room temperature. Plaster splints take between two and eight minutes to set, but they do not reach their maximum strength for approximately 24 hours. Plaster splints are easier to mold and are less expensive than fiberglass splints. However, they are more difficult to apply and become soggy when wet. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Customized plaster splints'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fiberglass and other synthetic splints (eg, Orthoglass&reg;, OCL&reg;, and Velcro splints) usually are already padded and easier to apply. In addition, synthetic splints set more quickly and are lighter, longer-wearing, and water-resistant. However, they are more expensive and do not mold as well as plaster splints. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Fiberglass splints'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kovan J, McKeag D. Ankle splinting, taping, and casting. In: Procedures for Primary Care Physicians, Pfenninger J, Fowler G.  (Eds), Mosby, St. Louis 1994. p.1004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15208/abstract/2\">",
"      Steele, P, Bush-Joseph, C, Bach, B Jr. Office management of trauma &ndash; management of acute fractures around the knee, ankle, and foot. Clin Fam Pract 2000; 2:661.",
"     </a>",
"    </li>",
"    <li>",
"     Chudnofsky C. Splinting techniques. In: Clinical Procedurs in Emergency Medicine, Roberts J, Hedges J.  (Eds), WB Saunders, Philadelphia 1998. p.852.",
"    </li>",
"    <li>",
"     Geideman J. Orthopedic injuries: General principles. In: Rosen's Emergency Medicine: Concepts and Clinical Practice, 5th, Marx J, Hockberger R, Walls R.  (Eds), Mosby, Philadelphia 2002. p.486.",
"    </li>",
"    <li>",
"     Klig J. Splinting procedures. In: Textbook of Pediatric Emergency Procedures, Henretig F, King C, Joffe M.  (Eds), Lippincott, Williams &amp; Wilkins, Baltimore 2008. p.919.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15208/abstract/6\">",
"      Howes DS, Kaufman JJ. Plaster splints: techniques and indications. Am Fam Physician 1984; 30:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15208/abstract/7\">",
"      Paras, R. Office management of trauma &ndash; upper extremity fractures. Clin Fam Pract 2000; 2:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15208/abstract/8\">",
"      Boutis K, Willan AR, Babyn P, et al. A randomized, controlled trial of a removable brace versus casting in children with low-risk ankle fractures. Pediatrics 2007; 119:e1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15208/abstract/9\">",
"      Plint AC, Perry JJ, Correll R, et al. A randomized, controlled trial of removable splinting versus casting for wrist buckle fractures in children. Pediatrics 2006; 117:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15208/abstract/10\">",
"      Stewart HD, Innes AR, Burke FD. Functional cast-bracing for Colles' fractures. A comparison between cast-bracing and conventional plaster casts. J Bone Joint Surg Br 1984; 66:749.",
"     </a>",
"    </li>",
"    <li>",
"     Ruddy RM. Illustrated techniques of pediatric emergency procedures. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.1861.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15208/abstract/12\">",
"      Boyd AS, Benjamin HJ, Asplund C. Principles of casting and splinting. Am Fam Physician 2009; 79:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15208/abstract/13\">",
"      Shaw DC, Heckman JD. Principles and techniques of splinting musculocutaneous injuries. Emerg Med Clin North Am 1984; 2:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15208/abstract/14\">",
"      Harrison BP, Hilliard MW. Emergency department evaluation and treatment of hand injuries. Emerg Med Clin North Am 1999; 17:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15208/abstract/15\">",
"      Kaplan SS. Burns following application of plaster splint dressings. Report of two cases. J Bone Joint Surg Am 1981; 63:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15208/abstract/16\">",
"      Boyd AS, Benjamin HJ, Asplund C. Splints and casts: indications and methods. Am Fam Physician 2009; 80:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15208/abstract/17\">",
"      Fitch MT, Nicks BA, Pariyadath M, et al. Videos in clinical medicine. Basic splinting techniques. N Engl J Med 2008; 359:e32.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6334 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15208=[""].join("\n");
var outline_f14_54_15208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17439119\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H576000\">",
"      Preformed splints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H576007\">",
"      Manufactured splints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BASIC PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMPLICATIONS OF SPLINTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SPLINT APPLICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Customized plaster splints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fiberglass splints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      UPPER EXTREMITY SPLINTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sling and swathe splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Velpeau bandage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sugar tong splints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Long arm splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Colles splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dorsal and/or volar splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gutter splint",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Thumb spica splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Finger splints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bulky hand compression dressing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3998419\">",
"      Figure-of-eight splint",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LOWER EXTREMITY SPLINTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Knee splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Jones compression dressing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Posterior leg splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Stirrup splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Bulky foot compression dressing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Buddy taping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28207296\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17439119\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6334\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6334|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/24/35200\" title=\"figure 1\">",
"      Position of function hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/7/26736\" title=\"figure 2\">",
"      Sling and swathe splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/12/10436\" title=\"figure 3\">",
"      Velpeau bandage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/12/5315\" title=\"figure 4\">",
"      Proximal sugar tong splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/26/37281\" title=\"figure 5\">",
"      Distal sugar tong splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/24/23951\" title=\"figure 6\">",
"      Long arm splints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/62/16352\" title=\"figure 7\">",
"      Colles splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/15/43263\" title=\"figure 8\">",
"      Volar forearm splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/0/10240\" title=\"figure 9\">",
"      Gutter splints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/19/26943\" title=\"figure 10\">",
"      Thumb spica splint 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/33/21008\" title=\"figure 11\">",
"      Figure of eight splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/16/17678\" title=\"figure 12\">",
"      Knee splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/6/36960\" title=\"figure 13\">",
"      Posterior leg splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/33/29200\" title=\"figure 14\">",
"      Stirrup splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42397\" title=\"figure 15\">",
"      Buddy taping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6334|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/23/14706\" title=\"picture 1\">",
"      Air cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/1/29718\" title=\"picture 2\">",
"      Splinting material",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/8/21635\" title=\"picture 3\">",
"      Finger buddy taping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/0/7183\" title=\"picture 4\">",
"      Burkhalter splint for metacarpal fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/10/38063\" title=\"picture 5\">",
"      Finger dorsal splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/41/32415\" title=\"picture 6\">",
"      Finger volar splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/0/12288\" title=\"picture 7\">",
"      Finger toad splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/58/25519\" title=\"picture 8\">",
"      Distal interphalangeal finger joint splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/2/22565\" title=\"picture 9\">",
"      Short leg splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/10/36015\" title=\"picture 10\">",
"      Bulky foot compression dressing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6334|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/47/21243\" title=\"table 1\">",
"      Positions of function selected joints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/35/12860\" title=\"table 2\">",
"      Upper extremity splints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/14/13547\" title=\"table 3\">",
"      Lower extremity splints",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12985?source=related_link\">",
"      Clavicle fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=related_link\">",
"      Closed reduction and casting of distal forearm fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16216?source=related_link\">",
"      Digit dislocation reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=related_link\">",
"      Distal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/15/44280?source=related_link\">",
"      Evaluation and management of pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=related_link\">",
"      Extensor tendon injury of the distal interphalangeal joint (mallet finger)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28581?source=related_link\">",
"      Flexor tendon injury of the distal interphalangeal joint (jersey finger)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40885?source=related_link\">",
"      Middle phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=related_link\">",
"      Patient information: Common wrist injuries (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20037?source=related_link\">",
"      Proximal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44008?source=related_link\">",
"      Treatment of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32068?source=related_link\">",
"      Ulnar collateral ligament injury (gamekeeper's or skier's thumb)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_54_15209="Tobramycin (systemic therapy and oral inhalation): Pediatric drug information";
var content_f14_54_15209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tobramycin (systemic therapy and oral inhalation): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?13/27/13753?source=see_link\">",
"    see \"Tobramycin (systemic therapy and oral inhalation): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/45/15061?source=see_link\">",
"    see \"Tobramycin (systemic therapy and oral inhalation): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9600299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9600303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      TOBI&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9600304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      TOBI&reg;;",
"     </li>",
"     <li>",
"      TOBI&reg; Podhaler&reg;;",
"     </li>",
"     <li>",
"      Tobramycin Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10574258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Aminoglycoside",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be based on actual weight unless the patient has hydrops fetalis. Dosage should be individualized based upon serum concentration monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General dosing; susceptible infection:",
"     </b>",
"     I.V.: Dosing strategies may vary by institution as a wide variety of dosing regimens have been studied. Consider single-dose administration with serum concentration monitoring in patients with urine output &lt;1 mL/kg/hour or serum creatinine &gt;1.3 mg/dL rather than scheduled dosing. Consider prolongation of dosing interval when coadministered with ibuprofen or indomethacin or in neonates with history of the following: Birth depression, birth hypoxia/asphyxia, or cyanotic congenital heart disease. Some dosing based on gentamicin studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Age-directed dosing",
"     </i>",
"     (de Hoog, 2002; DiCenzo, 2003; Hagen, 2009; Hansen, 2003; Ohler, 2000; Serane, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GA &lt;32 weeks: 4-5 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GA 32-36 weeks: 4-5 mg/kg/dose every 36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GA &ge;37 weeks: 4-5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     In some trials, a fixed interval of every 24 hours was used with dosages ranging from 2.5-4 mg/kg/dose based on GA (ie, lower doses were used for younger GA).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Weight-directed dosing",
"     </i>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PNA &le;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &le;2 kg: 5 mg/kg/dose every 48 hours; in ELBW neonates (&lt;1 kg), the dosing interval may need extended through first 2 weeks of life",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;2 kg:  4 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PNA 8-28 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &le;2 kg: 4-5 mg/kg/dose every 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;2 kg: 4 mg/kg/dose every 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10575235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/27/13753?source=see_link\">",
"      see \"Tobramycin (systemic therapy and oral inhalation): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be based on an estimate of ideal body weight. Some dosing is based on gentamicin studies. In morbidly obese children, adolescents, and adults, dosage requirement may best be estimated using a dosing weight of IBW + 0.4 (TBW - IBW). Dosage should be individualized based upon serum concentration monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing, susceptible infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Conventional dosing: I.M., I.V.: 2.5 mg/kg/dose every 8 hours; some pediatric patients may require larger doses (ie, patients undergoing continuous hemofiltration, patients with major burns, febrile granulocytopenic patients); modify dose based on individual patient requirements as determined by renal function, serum drug concentrations, and patient-specific clinical parameters",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer's labeling: I.M., I.V.: 2-2.5 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended-interval dosing: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Weight-directed: 4.5-7.5 mg/kg/dose every 24 hours (Contopoulos-Ioannidis, 2004;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Age-directed: Based on data from 114 patients, the following has been suggested (McDade, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     3 months to &lt;2 years: 9.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     2 to &lt;8 years: 8.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &ge;8 years: 7 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cystic fibrosis, pulmonary infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Conventional dosing: I.M., I.V.: 3.3 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended-interval dosing: I.V.: Initial: 10-12 mg/kg/dose every 24 hours (Flume, 2009; Smyth, 2005; Van Meter, 2009);",
"     <b>",
"      Note:",
"     </b>",
"     The CF Foundation recommends extended-interval dosing as preferred over conventional dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Intra-abdominal infection, complicated:",
"     </b>",
"     I.V.: 3-7.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 8-24 hours (Solomkin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      CNS infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Meningitis (Tunkel, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants and Children: I.V.: 7.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: I.V.: 5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     VP-shunt infection, ventriculitis: Limited data available: Intraventricular/intrathecal",
"     <b>",
"      (use a preservative-free preparation)",
"     </b>",
"     : 5-20 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Peritonitis (CAPD)",
"     </b>",
"     (Warady, 2000): Intraperitoneal: Continuous: Loading dose: 8  mg per liter of dialysate; maintenance dose: 4 mg per liter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pulmonary infection:",
"     </b>",
"     Inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Standard regimen",
"     </b>",
"     (cystic fibrosis patients): Children &ge;6 years and Adolescents: TOBI&reg;: 300 mg every 12 hours (do not administer doses less than 6 hours apart); administer in repeated cycles of 28 days on drug, followed by 28 days off drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Low-dose regimen",
"     </b>",
"     (noncystic fibrosis patients;",
"     <b>",
"      Note:",
"     </b>",
"     Used by some centers; no published data are available): Children and Adolescents: 40-80 mg/dose 2-3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      UTI:",
"     </b>",
"     Extended-interval dosing: I.V.: Based on data from 179 patients, the following age-directed dosing has been suggested (Carapetis, 2001):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1 month to &lt;5 years: 7.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     5-10 years: 6 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;10 years: 4.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Conventional:",
"     </b>",
"     I.M., I.V.: 1-2.5 mg/kg/dose every 8-12 hours; to ensure adequate peak concentrations early in therapy, higher initial dosage may be considered in selected patients when extracellular water is increased (edema, septic shock, postsurgical, or trauma)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Once daily:",
"     </b>",
"     I.V.: 4-7 mg/kg/dose once daily; some clinicians recommend this approach for all patients with normal renal function; this dose is at least as efficacious with similar, if not less, toxicity than conventional dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Inhalation (TOBI &reg;): 300 mg every 12 hours (do not administer doses &lt;6 hours apart); administer in repeated cycles of 28 days on drug followed by 28 days off drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Infants, Children, and Adolescents: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     The following adjustments have been recommended (Aronoff, 2007):",
"     <b>",
"      Note:",
"     </b>",
"     Renally adjusted dose recommendations are based on doses of  2.5 mg/kg/dose every 8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 12-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 18-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 48-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Intermittent hemodialysis: 2 mg/kg/dose; redose as indicated by serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Peritoneal dialysis (PD): 2 mg/kg/dose; redose as indicated by serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Continuous renal replacement therapy (CRRT): 2-2.5 mg/kg/dose every 12-24 hours, monitor serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Conventional dosing: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: Administer every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-60 mL/minute: Administer every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-40 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-20 mL/minute: Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     High-dose therapy: I.V.: Interval may be extended (eg, every 48 hours) in patients with moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-59 mL/minute) and/or adjusted based on serum concentration determinations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days) (Heintz, 2009): Dialyzable (25% to 75%; variable; dependent on filter, duration, and type of IHD);",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">",
"     Loading dose of 2-3 mg/kg loading dose followed by:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">",
"     Mild UTI or synergy: 1 mg/kg every 48-72 hours; consider redosing for pre-HD or post-HD serum concentrations &lt;1 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">",
"     Moderate to severe UTI: 1-1.5 mg/kg every 48-72 hours; consider redosing for pre-HD serum concentrations &lt;1.5-2 mcg/mL or post-HD serum concentrations &lt;1 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">",
"     Systemic gram negative rod infection: 1.5-2 mg/kg every 48-72 hours; consider redosing for  pre-HD concentrations &lt;3-5 mcg/mL or post-HD serum concentrations &lt;2 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Peritoneal dialysis (PD):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Administration via PD fluid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">",
"     Gram-positive infection (eg, synergy): 3-4 mg/L (3-4 mcg/mL) of PD fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">",
"     Gram-negative infection: 4-8 mg/L (4-8 mcg/mL) of PD fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Administration via I.V., I.M. route during PD: Dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute and follow serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CVVH/CVVHD/CVVHDF: I.V.: Loading dose of 2-3 mg/kg followed by:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Mild UTI or synergy: I.V.: 1 mg/kg every 24-36 hours (redose when serum concentration &lt;1 mcg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Moderate to severe UTI: I.V.: 1-1.5 mg/kg every 24-36 hours (redose when serum concentration &lt;1.5-2 mcg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Systemic gram-negative infection: I.V.: 1.5-2.5 mg/kg every 24-48 hours (redose when serum concentration &lt;3-5 mcg/mL)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9600442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS: 80 mg (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1.2 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (2 mL); 40 mg/mL (2 mL, 30 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TOBI&reg;: 300 mg/5 mL (56s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9600306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes solution for nebulization",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15390962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bethkis&reg;: FDA approved October 2012; availability is expected during the second or third quarter of 2013.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bethkis&reg; inhalation solution (300 mg/4 mL) is approved for the management of cystic fibrosis patients (&ge;6 years) with",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     TOBI&reg; Podhaler&trade;: FDA approved March 2013; availability anticipated in the second quarter of 2013.  Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10575236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalation (standard regimen): Use a PARI LC Plus&trade; reusable nebulizer and a DeVilbiss Pulmo-Aide&reg; air compressor for administration of tobramycin by inhalation; patient should be sitting or standing upright and breathing normally through the mouthpiece of the nebulizer. Nebulizer treatment period is usually over 15 minutes. If on multiple inhalation products, administer TOBI&reg; last.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: Administer undiluted by deep I.M. route if possible. Slower absorption and lower peak concentrations, probably due to poor circulation in the atrophic muscle, may occur following I.M. injection in paralyzed patients, suggest I.V. route.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Administer by slow intermittent infusion over 30-60 minutes (administer higher doses over 60 minutes) or by direct injection over 15 minutes; final I.V. concentration for administration should not exceed 10 mg/mL; administer beta-lactam antibiotics, such as penicillins and cephalosporins, at least 1 hour before or after tobramycin; simultaneous administration may result in reduced antibacterial efficacy",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9600361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 40 10% in dextrose, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, mannitol 20%, LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aldesleukin, alprostadil, amifostine, amiodarone, amsacrine, anidulafungin, aztreonam, bivalirudin, caspofungin, cefepime, ceftazidime, ciprofloxacin, cisatracurium, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, doripenem, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, foscarnet, furosemide, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, IL-2, insulin (regular), labetalol, linezolid, magnesium sulfate, melphalan, meperidine, midazolam, morphine, nicardipine, oxytocin, remifentanil, tacrolimus, telavancin, teniposide, theophylline, thiotepa, tigecycline, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, azithromycin, drotrecogin alfa, heparin, hetastarch in NS, indomethacin, pantoprazole, pemetrexed, piperacillin, piperacillin/tazobactam, propofol, sargramostim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Heparin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Diphenhydramine, doxapram.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Clindamycin, heparin, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10574284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Powder for injection: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). After reconstitution, solutions remain stable for 24 hours at room temperature and 96 hours when refrigerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Solution for injection: Store intact vials at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premixed solution (manufacturer premixed): Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from freezing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, for inhalation (TOBI&reg;): Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). May be stored in foil pouch at room temperature of 25&deg;C (77&deg;F) for up to 28 days. Avoid intense light. Do not use if cloudy or contains particles; a darkened yellow solution does not indicate loss of potency; incompatible with dornase alfa (may precipitate).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10574260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of documented or suspected infections caused by susceptible gram-negative bacilli, including",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     ; nonpseudomonal enteric bacillus infection which is more susceptible to tobramycin than gentamicin based on microbiology testing; susceptible organisms in lower respiratory tract infections (FDA approved in adults), serious central nervous system infection caused by susceptible organisms (FDA approved in adults), septicemia (FDA approved in all ages); intra-abdominal, skin, bone, soft tissue, and urinary tract infections (FDA approved in adults); has also been used for empiric therapy in cystic fibrosis and immunocompromised patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalation: Management of cystic fibrosis patients with",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9600301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tobramycin may be confused with Trobicin&reg;, vancomycin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nebcin [Multiple international markets] may be confused with Naprosyn brand name for naproxen [U.S., Canada, and multiple international markets]; Nubain brand name for nalbuphine [Multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9600333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion, disorientation, dizziness, fever, headache, lethargy, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Exfoliative dermatitis, itching, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Decreased serum calcium, magnesium, potassium, and/or sodium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, eosinophilia, granulocytopenia, leukocytosis, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, bilirubin increased, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Hearing loss, ototoxicity (auditory), ototoxicity (vestibular), roaring in the ears, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Cylindruria, increased BUN, increased serum creatinine, oliguria, proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Inhalation",
"     </b>",
"     (as reported for solution for inhalation unless otherwise noted):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest discomfort (powder for inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Malaise, pyrexia (powder for inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abnormal taste (powder for inhalation), diarrhea, sputum discoloration, xerostomia (powder for inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Eosinophilia, RBC sedimentation rate increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: FEV",
"     <sub>",
"      1",
"     </sub>",
"     decreased, rales, voice alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rare but important or life-threatening: Aphonia, bronchial secretions increased, deafness, exercise tolerance decreased, hearing loss, hypersensitivity (allergic reactions), hypoesthesia (oral), lower respiratory tract infection, musculoskeletal chest pain, nasal congestion, obstructive airway disorder, oral candidiasis, pneumonitis, pruritus, pulmonary congestion, rash, respiratory sounds abnormal, serum glucose increased, urticaria, vital capacity decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10574261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tobramycin, any component or other aminoglycosides",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10574265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with pre-existing renal impairment; modify dosage in patients with renal impairment; monitor renal and eighth nerve function in patients with known or suspected renal impairment",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Use with caution in patients with auditory or vestibular impairment. Use with caution in patients with myasthenia gravis, hypocalcemia, and in conditions which depress neuromuscular transmission; may cause neuromuscular blockade and respiratory paralysis; risk increased with concomitant use of anesthesia or muscle relaxants. Use with caution in pediatric patients on extracorporeal membrane oxygenation (ECMO); pharmacokinetics of aminoglycosides may be altered; dosage adjustment and close monitoring necessary.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Cross-allergenicity with other aminoglycosides has been observed. Avoid intramuscular administration in paralyzed patients due to poor circulation in the atrophic muscles which may result in slower absorption and lower peak serum concentrations; use intravenous route.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10574263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aminoglycosides are associated with significant nephrotoxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Neurotoxicity, manifested as vestibular and permanent bilateral auditory ototoxicity, can occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; tinnitus or vertigo are indications of vestibular injury and impending bilateral irreversible deafness; early ototoxicity usually affects high-pitched sound. Risk of nephrotoxicity and ototoxicity is increased in patients with impaired renal function, dehydration, high-dose therapy, or prolonged therapy. Peak and trough serum concentrations of aminoglycosides should be monitored periodically during therapy to assure adequate levels and to avoid potentially toxic levels",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Ototoxicity is associated with high serum concentrations persisting for prolonged periods; nephrotoxicity is associated with high serum trough concentrations. Risk of nephrotoxicity increases when used concurrently with other potentially nephrotoxic drugs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; renal damage is usually reversible. Risk of ototoxicity increases with use of potent diuretics",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Aminoglycosides can cause fetal harm when administered to a pregnant woman",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; aminoglycosides have been associated with several reports of total irreversible bilateral congenital deafness in pediatric patients exposed",
"     <i>",
"      in utero",
"     </i>",
"     . Use with caution in premature infants and neonates",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; immature renal function may increase risk of accumulation and related toxicity. Some formulations contain sulfites which may cause allergic reactions in susceptible individuals. Not intended for long-term therapy due to toxic hazards associated with extended administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Inhalation: Transient tinnitus and hearing loss have been reported in tobramycin inhalation-treated patients; bronchospasm can occur with inhalation of tobramycin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9600351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9600308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9600309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Aminoglycosides may cause fetal harm if administered to a pregnant woman.",
"     </b>",
"     There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy; therefore, tobramycin is classified as pregnancy category D. Tobramycin crosses the placenta and produces detectable serum levels in the fetus. Although serious side effects to the fetus have not been reported following maternal use of tobramycin, a potential for harm exists.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of tobramycin may be altered. Pregnant women have an average-to-larger volume of distribution which may result in lower serum peak levels than for the same dose in nonpregnant women. Serum half-life is also shorter.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10575237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinalysis, urine output, BUN, serum creatinine, peak and trough serum tobramycin concentrations;",
"     <b>",
"      Note:",
"     </b>",
"     Do not use fingerstick for obtaining blood sample in patients concurrently receiving inhaled tobramycin as it may result in falsely elevated drug concentrations); be alert to ototoxicity, audiograms",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     With conventional dosing, typically obtain serum concentration after the third dose; exceptions for earlier monitoring may include neonates, patients with rapidly changing renal function, or patients receiving extended-interval dosing. Not all pediatric patients who receive aminoglycosides require monitoring of serum aminoglycoside concentrations. Indications for use of aminoglycoside serum concentration monitoring include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Treatment course &gt;5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients with decreased or changing renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients with a poor therapeutic response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates and Infants &lt;3 months of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Atypical body constituency (obesity, expanded extracellular fluid volume)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clinical need for higher doses or shorter intervals (cystic fibrosis, burns, endocarditis, meningitis, relatively resistant organism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients on hemodialysis or chronic ambulatory peritoneal dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Signs of nephrotoxicity or ototoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Concomitant use of other nephrotoxic agents",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients on high-dose aerosolized tobramycin: Consider obtaining peak tobramycin concentration 1 hour following inhalation to identify patients who are significant absorbers, in patients with decreased glomerular filtration rate, in patients on concomitant parenteral therapy, and in infants (Abdulhamid, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10575238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Traditional dosing: Timing of serum samples: Draw peak 30 minutes after 30-minute infusion has been completed or 1 hour following I.M. injection or beginning of infusion; draw trough immediately before next dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Therapeutic concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Peak:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Serious infections: 6-8 mcg/mL (12-17 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Life-threatening infections: 8-10 mcg/mL (17-21 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Urinary tract infections: 4-6 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Synergy against gram-positive organisms: 3-5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Trough:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Serious infections: 0.5-1 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Life-threatening infections: 1-2 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     The American Thoracic Society (ATS) recommends trough levels of &lt;1 mcg/mL for adult patients with hospital-acquired pneumonia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Timing of serum samples: Draw peak 30 minutes after completion of 30-minute infusion or at 1 hour following initiation of infusion or I.M. injection; draw trough within 30 minutes prior to next dose; aminoglycoside levels measured from blood taken from Silastic&reg; central catheters can sometimes give falsely elevated readings",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended-interval:",
"     <b>",
"      Note:",
"     </b>",
"     Pediatric therapeutic monitoring protocols have not been standardized; peak values are 2-3 times greater with extended-interval dosing regimens compared to traditional dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Noncystic fibrosis patients: Consider monitoring tobramycin serum concentration 18-20 hours after the start of the infusion to ensure the drug-free interval does not exceed typical postantibiotic effect (PAE) duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cystic fibrosis patients: Clinically two methods are utilized. Peak: 25-35 mcg/mL (some centers use 20-30 mcg/mL); 18- to 20-hour value: Detectable but &lt;1 mcg/mL; trough: Nondetectable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Method A: Obtain two serum concentrations at least 1 half-life apart after distribution is complete (eg, obtain a serum concentration 2 hours and 10 hours after the start of the infusion), calculate elimination rate and extrapolate a C",
"     <sub>",
"      max",
"     </sub>",
"     and C",
"     <sub>",
"      min",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Method B: Obtain a peak serum concentration 60 minutes after a 60-minute infusion and a serum concentration 18-20 hours after the start of the infusion to ensure the drug-free interval does not exceed typical postantibiotic effect (PAE) duration (4-6 hours)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10574285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits cellular initiation of bacterial protein synthesis by binding to 30S and 50S ribosomal subunits, resulting in a defective bacterial cell membrane",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13191158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Displays concentration-dependent killing; bacteriocidal",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10574286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Inhalation: Low systemic bioavailability; accumulation can occur in patients with a low glomerular filtration rate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Peak serum concentration following inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Solution for inhalation: ~1 mcg/mL following a 300 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Powder for inhalation: ~1 mcg/mL (range: 0.49-1.55 mcg/mL) following a 112 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Distributes primarily in the extracellular fluid volume; poor penetration into the CSF; drug accumulates in the renal cortex; small amounts distribute into bile, sputum, saliva, and tears",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Higher in neonates than older pediatric and adult patients; also increased in patients with edema, ascites, fluid overload; decreased in patients with dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Systemic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Neonates: 0.45 &plusmn; 0.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants: 0.4 &plusmn; 0.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children: 0.35 &plusmn; 0.15 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: 0.3 &plusmn; 0.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adults: 0.2-0.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Inhalation: Tobramycin remains concentrated primarily in the airways",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &lt;30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &le;1200 g: 11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;1200 g: 2-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: 4 &plusmn; 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 2 &plusmn; 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents: 1.5 &plusmn; 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults with normal renal function: 2-3 hours, directly dependent upon glomerular filtration rate; impaired renal function: 5-70 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: Within 30-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 30 minutes after a 30-minute infusion;",
"     <b>",
"      Note:",
"     </b>",
"     Distribution may be prolonged after larger doses. One study reported a 1.7-hour distribution period after a 60-minute, high-dose aminoglycoside infusion (Demczar, 1997).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: With normal renal function, 93% of dose excreted in urine within 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Dialyzable (25% to 70%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10575240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/45/15061?source=see_link\">",
"      see \"Tobramycin (systemic therapy and oral inhalation): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink adequate amounts of water unless instructed to restrict fluid intake. May experience ringing in ears, dizziness, blurred vision, GI upset, loss of appetite, or photosensitivity. Report severe headache, changes in hearing acuity, ringing in ears, change in balance, changes in urine pattern, persistent diarrhea, respiratory difficulty, rash, fever, unhealed sores, sores in mouth, vaginal drainage, muscle or bone pain, change in gait, or worsening of condition.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F15513444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy",
"     <i>",
"      in vivo",
"     </i>",
"     , particularly in the setting of profound renal impairment; however, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abdulhamid I, Wise TL, Andrews S, et al, \"Elevated Serum Tobramycin Concentrations After Treatment With Tobramycin Inhalation in a Preterm Infant,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2008, 28(7):939-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/18576909/pubmed\" id=\"18576909\" target=\"_blank\">",
"        18576909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartel K, Habash T, Lugauer S, et al, \"Optimal Tobramycin Dosage in Patients With Cystic Fibrosis &minus; Evidence for Predictability Based on Previous Drug Monitoring,\"",
"      <i>",
"       Infection",
"      </i>",
"      , 1999, 27(4-5):268-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/10885841/pubmed\" id=\"10885841\" target=\"_blank\">",
"        10885841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carapetis JR, Jaquiery AL, Buttery JP, et al, \"Randomized, Controlled Trial Comparing Once Daily and Three Times Daily Gentamicin in Children With Urinary Tract Infections,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2001, 20(3):240-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/11303823/pubmed\" id=\"11303823\" target=\"_blank\">",
"        11303823",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al, \"Extended-Interval Aminoglycoside Administration for Children: A Meta-Analysis,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(1):e111-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/15231982/pubmed\" id=\"15231982\" target=\"_blank\">",
"        15231982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Hoog M, Mouton JW, Schoemaker RC, et al, \"Extended-Interval Dosing of Tobramycin in Neonates: Implications for Therapeutic Drug Monitoring,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2002, 71(5):349-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/12011820/pubmed\" id=\"12011820\" target=\"_blank\">",
"        12011820",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Demczar DJ, Nafziger AN, and Bertino JS Jr, \"Pharmacokinetics of Gentamicin at Traditional Versus High Doses: Implications for Once-Daily Aminoglycoside Dosing,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1997, 41(5):1115-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/9145878/pubmed\" id=\"9145878\" target=\"_blank\">",
"        9145878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DiCenzo R, Forrest A, Slish JC, et al, \"A Gentamicin Pharmacokinetic Population Model and Once-Daily Dosing Algorithm for Neonates,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(5):585-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/12741432/pubmed\" id=\"12741432\" target=\"_blank\">",
"        12741432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flume PA, Mogayzel PJ Jr, Robinson KA, et al, \"Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations,\"",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2009, 180(9):802-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/19729669/pubmed\" id=\"19729669\" target=\"_blank\">",
"        19729669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilbert DN, \"Once-Daily Aminoglycoside Therapy,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(3):399-405.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/2039189 /pubmed\" id=\"2039189 \" target=\"_blank\">",
"        2039189",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green TP, Mirkin BL, Peterson PK, et al, \"Tobramycin Serum Level Monitoring in Young Patients With Normal Renal Function,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1984, 9(5):457-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/6499344/pubmed\" id=\"6499344\" target=\"_blank\">",
"        6499344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hagen I and &Oslash;ymar K, \"Pharmacological Differences Between Once Daily and Twice Daily Gentamicin Dosage in Newborns With Suspected Sepsis,\"",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2009, 31(1):18-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/18982422/pubmed\" id=\"18982422\" target=\"_blank\">",
"        18982422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hansen A, Forbes P, Arnold A, et al, \"Once-Daily Gentamicin Dosing for the Preterm and Term Newborn: Proposal for a Simple Regimen That Achieves Target Levels,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 2003, 23(8):635-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/14647159/pubmed\" id=\"14647159\" target=\"_blank\">",
"        14647159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knoderer CA, Everett JA, and Buss WF, \"Clinical Issues Surrounding Once-Daily Aminoglycoside Dosing in Children,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):44-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/12523459/pubmed\" id=\"12523459\" target=\"_blank\">",
"        12523459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kraus DM, Pai MP, and Rodvold KA, \"Efficacy and Tolerability of Extended-Interval Aminoglycoside Administration in Pediatric Patients,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2002, 4(7):469-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/12083974/pubmed\" id=\"12083974\" target=\"_blank\">",
"        12083974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Massie J and Cranswick N, \"Pharmacokinetic Profile of Once Daily Intravenous Tobramycin in Children With Cystic Fibrosis,\"",
"      <i>",
"       J Paediatr Child Health",
"      </i>",
"      , 2006, 42(10):601-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/16972966/pubmed\" id=\"16972966\" target=\"_blank\">",
"        16972966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDade EJ, Wagner JL, Moffett BS, et al, \"Once-Daily Gentamicin Dosing in Pediatric Patients Without Cystic Fibrosis,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010, 30(3):248-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/20180608/pubmed\" id=\"20180608\" target=\"_blank\">",
"        20180608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mouton JW, Jacobs N, Tiddens H, et al, \"Pharmacodynamics of Tobramycin in Patients With Cystic Fibrosis,\"",
"      <i>",
"       Diagn Microbiol Infect Dis",
"      </i>",
"      , 2005, 52(2):123-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/15964500/pubmed\" id=\"15964500\" target=\"_blank\">",
"        15964500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nahata MC, Powell DA, Durrell DE, et al, \"Effect of Gestational Age and Birth Weight on Tobramycin Kinetics in Newborn Infants,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1984, 14(1):59-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/6480541/pubmed\" id=\"6480541\" target=\"_blank\">",
"        6480541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohler KH, Menke JA, and Fuller L, \"Use of Higher Dose Extended Interval Aminoglycosides in a Neonatal Intensive Care Unit,\"",
"      <i>",
"       Am J Perinatol",
"      </i>",
"      , 2000, 17(6):285-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/11144309/pubmed\" id=\"11144309\" target=\"_blank\">",
"        11144309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramsey BW, Pepe MS, Quan JM, et al, \"Intermittent Administration of Inhaled Tobramycin in Patients With Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(1):23-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/9878641/pubmed\" id=\"9878641\" target=\"_blank\">",
"        9878641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012, 808-16.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Redmann S, Wainwright C, Stacey S, et al, \"Misleading High Tobramycin Plasma Concentrations Can Be Caused by Skin Contamination of Fingerprick Blood Following Inhalation of Nebulized Tobramycin (TOBI): A Short Report,\"",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2005, 27(2):205-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/15795653/pubmed\" id=\"15795653\" target=\"_blank\">",
"        15795653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Serane TV, Zengeya S, Penford G, et al, \"Once Daily Dose Gentamicin in Neonates - Is Our Dosing Correct?\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 2009, 98(7):1100-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/19397541/pubmed\" id=\"19397541\" target=\"_blank\">",
"        19397541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaw PK, Braun TL, Liebergen A, et al, \"Aerosolized Tobramycin Pharmacokinetics in Cystic Fibrosis Patients,\"",
"      <i>",
"       J Pediatr Pharm Pract",
"      </i>",
"      , 1997, 2(1):23-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smyth A, Tan KH, Hyman-Taylor P, et al, \"Once Versus Three-Times Daily Regimens of Tobramycin Treatment for Pulmonary Exacerbations of Cystic Fibrosis &minus; The TOPIC Study: A Randomised Controlled Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 365(9459):573-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/15708100/pubmed\" id=\"15708100\" target=\"_blank\">",
"        15708100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Meter DJ, Corriveau M, Ahern JW, et al, \"A Survey of Once-Daily Dosage Tobramycin Therapy in Patients With Cystic Fibrosis,\"",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2009, 44(4):325-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/19330772/pubmed\" id=\"19330772\" target=\"_blank\">",
"        19330772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warady BA, Schaefer F, Holloway M, et al, \"Consensus Guidelines for the Treatment of Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis,\"",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 2000, 20(6):610-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/54/15209/abstract-text/11216549/pubmed\" id=\"11216549\" target=\"_blank\">",
"        11216549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16058 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15209=[""].join("\n");
var outline_f14_54_15209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600299\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600303\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600304\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574258\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445209\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10575235\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600442\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600306\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15390962\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10575236\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600361\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574284\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574260\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600301\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600333\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574261\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574265\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574263\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300149\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600351\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600308\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600309\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10575237\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10575238\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574285\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13191158\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574286\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10575240\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513444\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16058\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16058|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/20/41283?source=related_link\">",
"      Tobramycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/31/25076?source=related_link\">",
"      Tobramycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/59/35762?source=related_link\">",
"      Tobramycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/27/13753?source=related_link\">",
"      Tobramycin (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/45/15061?source=related_link\">",
"      Tobramycin (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_54_15210="Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients";
var content_f14_54_15210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/54/15210/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15210/contributors\">",
"     Gary M Cox, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15210/contributors\">",
"     John R Perfect, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/54/15210/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15210/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15210/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/54/15210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/54/15210/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/54/15210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of cryptococcal meningoencephalitis consists of antifungal therapy, managing intracranial pressure, and reducing immunosuppressive therapy. The choice of the antifungal regimen varies depending on the nature of the host and extent of disease.",
"   </p>",
"   <p>",
"    Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites or cryptococcal antigen titer &ge;1:512) should be managed as for central nervous system disease, even in the setting of normal findings on spinal fluid examination.",
"   </p>",
"   <p>",
"    Principles of therapy for cryptococcal meningoencephalitis are comparable for infection due to either C. neoformans or C. gattii. As cryptococcomas are especially common with C. gattii infection, careful followup for development of hydrocephalus is warranted.",
"   </p>",
"   <p>",
"    Issues related to treatment of cryptococcal meningoencephalitis in HIV seronegative patients will be reviewed here. In general, the recommendations outlined in the following sections are in accordance with the 2010 Infectious Diseases Society of America practice guidelines for the management of cryptococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. Issues related to patients with HIV infection are discussed separately, as are issues related to cryptococcal infection outside the central nervous system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=see_link\">",
"     \"Cryptococcal infection outside the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIFUNGAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of cryptococcal meningoencephalitis consists of antifungal therapy including induction, consolidation, and maintenance phases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The choice of the antifungal regimen varies depending on the nature of the host and extent of disease. Antifungal regimens for organ transplant recipients and non-HIV infected, nontransplant hosts are discussed below. These strategies are largely extrapolated from studies of patients with HIV infection.",
"   </p>",
"   <p>",
"    Prevention and management of the toxicities associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=see_link\">",
"     \"Pharmacology of flucytosine (5-FC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Organ transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of cryptococcal meningoencephalitis in organ transplant recipients is as outlined in the following sections (",
"    <a class=\"graphic graphic_table graphicRef56336 \" href=\"UTD.htm?42/59/43963\">",
"     table 1",
"    </a>",
"    ). Antifungal therapy should be administered together with adjustment in the immunosuppressive regimen. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Modulating immunosuppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Induction therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction therapy for solid organ transplant recipients with cryptococcal meningoencephalitis consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV per day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV per day) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally in four divided doses, adjusted for renal function) for at least two weeks (",
"    <a class=\"graphic graphic_table graphicRef56336 \" href=\"UTD.htm?42/59/43963\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the frequency of reduced renal function in transplant recipients (approximately 25 percent have creatinine &gt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and the risk of nephrotoxicity associated with concurrent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate and calcineurin inhibitors, amphotericin B deoxycholate should be used with caution and is",
"    <strong>",
"     not",
"    </strong>",
"    recommended as first-line therapy in this population. If used, the tolerated dose is uncertain; 0.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day with frequent renal function monitoring may be used.",
"   </p>",
"   <p>",
"    In a prospective cohort study of 75 solid organ transplant recipients with CNS cryptococcosis who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , those who received a lipid formulation had lower 90-day mortality on multivariate analysis than those who received the deoxycholate formulation (odds ratio 0.11, 95% CI 0.02-0.57) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/3\">",
"     3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     Amphotericin B lipid complex",
"    </a>",
"    has been used successfully for cryptococcal meningoencephalitis in salvage regimens and is also acceptable for patients with amphotericin B deoxycholate toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     Flucytosine",
"    </a>",
"    is used as an adjunct to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    for the first two weeks of therapy because the combination of agents provides greater early fungicidal activity than amphotericin B alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In addition, the absence of flucytosine is associated with lack of CSF sterilization at week two and treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Combination therapy with amphotericin B plus flucytosine also results in lower mortality compared with amphotericin B monotherapy or combination therapy with amphotericin B plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/7\">",
"     7",
"    </a>",
"    ]. Most of the data regarding the use of flucytosine come from studies of HIV-positive individuals. In the cohort study of solid organ transplant recipients described above, there was no difference in mortality between patients who received lipid formulations of amphotericin B with or without flucytosine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the number of patients who received flucytosine may have been inadequate to provide meaningful results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23929?source=see_link&amp;anchor=H5331892#H5331892\">",
"     \"Treatment of cryptococcal meningoencephalitis in HIV-infected patients\", section on 'Induction and consolidation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Careful attention to serum levels is warranted to avoid bone marrow toxicity, particularly in patients with renal dysfunction. Measurement of serum 5-FC concentrations is recommended after three to five days of therapy, when available, and should be obtained two hours after a dose has been administered [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. Guidelines for the treatment of cryptococcal infections recommend peak concentrations between 30 and 80",
"    <span class=\"nowrap\">",
"     mcg/mL;",
"    </span>",
"    concentrations &gt;100",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. Serum drug concentrations should be repeated if renal function worsens, or if leukopenia or thrombocytopenia occurs. With decreasing renal function (often due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ), toxicity is more common and patients must be monitored particularly carefully. If amphotericin B-induced nephrotoxicity occurs, the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    should be reduced.",
"    <br/>",
"    <br/>",
"    All patients receiving flucytosine should undergo regular monitoring of complete blood counts (CBC). In settings in which serum 5-FC concentrations are not available, CBC monitoring two to three times per week provides an indirect method of screening for excessive dosing. An otherwise unexplained reduction in the neutrophil or platelet count may reflect flucytosine toxicity and either the drug should be stopped or the dose reduced. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=see_link&amp;anchor=H12#H12\">",
"     \"Pharmacology of flucytosine (5-FC)\", section on 'Serum concentration monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If induction therapy does not include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    , it may be appropriate to extend administration of one of the above",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulations for at least four to six weeks of induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. In cases with high fungal burden of disease or relapse, higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) could be considered. However, a randomized controlled trial that compared doses of 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in AIDS patients found that the higher dose was safe, but not more efficacious than the lower dose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23929?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2294041\">",
"    <span class=\"h4\">",
"     Repeat lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with positive baseline CSF cultures should undergo repeat lumbar puncture after two weeks of induction therapy; lumbar puncture may have to be repeated sooner for management of increased intracranial pressure or concern about potential microbiologic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. Most persistently positive cryptococcal cultures found in patients who are on therapy grow within two weeks; generally laboratories keep fungal cultures for three to four weeks for detection of fungal growth.",
"   </p>",
"   <p>",
"    Patients whose cerebrospinal fluid (CSF) cultures remain positive despite two weeks of induction therapy should continue the induction regimen with serial lumbar punctures every two weeks until the CSF becomes sterile [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. In a small prospective study of CNS cryptococcosis in transplant patients, the median time to CSF sterilization was 10 days (mean, 16 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serial evaluation of CSF or serum cryptococcal antigen test is not appropriate for evaluating response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/12\">",
"     12",
"    </a>",
"    ]. These do not correlate with CSF sterilization at two weeks or outcome at 180 days [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\", section on 'Cryptococcal antigen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Organ transplant recipients whose CSF cultures are anticipated to be negative after two weeks of induction therapy and who do not have neurological complications may proceed to consolidation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Consolidation and maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following induction therapy, consolidation therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 to 800 mg [6 to 12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    orally daily) for eight weeks should be administered, followed by maintenance therapy with fluconazole (200 to 400 mg orally daily) for 6 to 12 months (",
"    <a class=\"graphic graphic_table graphicRef56336 \" href=\"UTD.htm?42/59/43963\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach to consolidation and maintenance therapy has been associated with a very low relapse rate; in a prospective study of 79 solid organ transplant recipients in whom maintenance therapy was employed for a median of 183 days, the risk of relapse was 1.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/11\">",
"     11",
"    </a>",
"    ]. Among those who did not receive maintenance therapy, relapse rates were high, and all were documented within one year after cessation of antifungal therapy (median 3.5 months). Prior to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    for maintenance therapy, the rate of relapse of cryptococcal meningoencephalitis in non-HIV infected patients ranged from 15 to 25 percent; most relapses occur within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/13\">",
"     13",
"    </a>",
"    ]. Therefore, chronic maintenance azole therapy is generally given for one year after diagnosis of disease; longer therapy may be warranted in those receiving very high doses of immunosuppressants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Non-HIV infected, nontransplant hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cryptococcal infection in the absence of HIV or organ transplantation appear to have less severe host immune defects, although the potential management challenges should not be underestimated given the heterogeneous nature of this group. Underlying conditions may include idiopathic CD4 lymphocytopenia, connective tissue disease, malignancy, or chronic glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Seemingly immunocompetent patients may also develop cryptococcal infection. Given the heterogeneity of this population, management must be tailored to individual patient circumstances.",
"   </p>",
"   <p>",
"    In general, non-HIV infected, nontransplant hosts with cryptococcal meningoencephalitis should be treated as outlined in the following sections (",
"    <a class=\"graphic graphic_table graphicRef77297 \" href=\"UTD.htm?25/61/26588\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, non-HIV infected, nontransplant hosts with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites or cryptococcal antigen titer &ge;1:512) should also be managed as outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Induction therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction therapy for non-HIV infected, nontransplant hosts with cryptococcal meningoencephalitis consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (0.7 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally in four divided doses) for at least four weeks (",
"    <a class=\"graphic graphic_table graphicRef77297 \" href=\"UTD.htm?25/61/26588\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. In studies of HIV-infected patients, this regimen led to a greater survival benefit and was more fungicidal than amphotericin B monotherapy or amphotericin B in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23929?source=see_link&amp;anchor=H5331892#H5331892\">",
"     \"Treatment of cryptococcal meningoencephalitis in HIV-infected patients\", section on 'Induction and consolidation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who present with positive baseline CSF cultures, severe symptoms, or significant underlying immunosuppression should undergo repeat lumbar puncture after two weeks of induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. Lumbar puncture may be repeated sooner for management of increased intracranial pressure or concern about potential microbiologic failure. Most persistently positive cryptococcal cultures that are found in patients who are on therapy grow within two weeks; generally laboratories keep fungal cultures for three to four weeks for detection of fungal growth.",
"   </p>",
"   <p>",
"    Patients whose CSF cultures remain positive after two weeks of induction therapy should continue the induction regimen with serial lumbar punctures every two weeks until the CSF becomes sterile. For patients who have negative CSF cultures but have neurologic complications, induction therapy may be extended for a total of six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with cryptococcal meningoencephalitis in the absence of HIV or organ transplantation whose CSF cultures are negative after two weeks of induction therapy and who do not have neurological complications can receive two additional weeks of induction therapy (four weeks total) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. However, for patients at low risk for therapeutic failure (eg, early diagnosis, no underlying immunocompromising condition, and excellent clinical response to initial two weeks of combination antifungal therapy), it may be reasonable to stop induction therapy after two weeks and proceed with consolidation therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    at a high dose (800 mg [12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    per day orally) for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who do not have severe symptoms and who are not immunosuppressed may not need a surveillance lumbar puncture as long as they show a clear clinical response to induction therapy.",
"   </p>",
"   <p>",
"    In the setting of drug intolerance, lipid formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    [3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    [5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IV]) may be substituted for amphotericin B deoxycholate. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Limited drug tolerance or availability'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    should be monitored as outlined in the preceding section. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Organ transplant recipients'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=see_link\">",
"     \"Pharmacology of flucytosine (5-FC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If induction therapy does not include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    , it may be appropriate to administer one of the above formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    for at least two additional weeks of induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Consolidation and maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following induction therapy, consolidation therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 mg [6",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    orally daily) should be administered for eight weeks (",
"    <a class=\"graphic graphic_table graphicRef77297 \" href=\"UTD.htm?25/61/26588\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. For those patients who were deemed to be at low risk for therapeutic failure as described above and who received only two weeks of induction therapy, consolidation therapy should consist of higher doses of fluconazole (800 mg [12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    orally per day) for eight weeks.",
"   </p>",
"   <p>",
"    Subsequently, maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (200 mg [3",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    orally daily) should be administered for 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rationale for consolidation and maintenance therapy is as outlined in the preceding section. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Consolidation and maintenance therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Limited drug tolerance or availability",
"    </span>",
"    &nbsp;&mdash;&nbsp;For circumstances in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate is not tolerated or available, lipid formulations of amphotericin B (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    [3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    [5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily]) may be substituted. In general, amphotericin B deoxycholate dosages of 0.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day with adjunctive saline infusions are generally well tolerated for two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/5,6,16\">",
"     5,6,16",
"    </a>",
"    ]. Data about lipid formulation amphotericin agents in patients without HIV infection are outlined above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Organ transplant recipients'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For circumstances in which no amphotericin formulations are tolerated or available,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (800 to 1200 mg orally per day) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally per day in four divided doses) may be administered for 2 to 10 weeks, followed by maintenance therapy with fluconazole (200 to 400 mg per day orally) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1,17-19\">",
"     1,17-19",
"    </a>",
"    ]. Liver function tests should be monitored closely when this combination is used. If flucytosine cannot be given, fluconazole (800 to 1200 mg orally per day) may be administered for at least 10 weeks or until CSF culture results are negative, followed by maintenance therapy with fluconazole (200 to 400 mg orally daily).",
"   </p>",
"   <p>",
"    For circumstances in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    is not tolerated or available,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (0.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (800 mg [12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    orally daily) may be administered for two weeks, followed by consolidation with fluconazole (800 mg orally daily) for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. Maintenance therapy is fluconazole (200 to 400 mg orally daily).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Persistent or relapsed infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent infection refers to persistently positive CSF cultures after four weeks of appropriate antifungal therapy. Relapse of infection refers to resolution of infection followed by subsequent recurrence as demonstrated by both recovery of viable cryptococci from a sterile site as well as recrudescence of signs and symptoms at a previous site of disease. Most cases are attributable to inadequate primary therapy (dose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    duration) or insufficient adherence to consolidation or maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    therapy.",
"   </p>",
"   <p>",
"    Risk factors for relapse include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low initial CSF white blood cell counts",
"     </li>",
"     <li>",
"      Persistently low CSF glucose concentration after 4 weeks of therapy",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (&ge;20 mg) or equivalent after completion of antifungal therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Distinguishing between persistent or relapsed cryptococcal infection, immune reconstitution inflammatory syndrome (IRIS) and other infections or complications can be difficult in severely immunocompromised individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Clinical manifestations, inflammatory CSF values, positive India ink exams and positive cryptococcal antigen titer may be present in both IRIS and cryptococcal infection. The most important distinguishing feature is that patients with active infection have positive CSF cultures, whereas patients with IRIS have sterile CSF cultures.",
"   </p>",
"   <p>",
"    Initial management of persistent or relapsed infection should include evaluation of immunosuppressive therapy and management of increased intracranial pressure. Repeat induction phase therapy should be reinstituted for a longer course (4 to 10 weeks) and a surveillance lumbar puncture should be performed after two weeks of therapy. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    dose may be increased; for amphotericin B deoxycholate the upper limit of the dosing range is 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    has been used at 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily for treating cryptococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungal isolates should be evaluated for changes in the minimum inhibitory concentration (MIC) from the original isolate; a &ge;3-dilution difference suggests development of drug resistance. A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    MIC of &ge;16",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    MIC of &ge;32",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is considered resistant and alternative agents should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/23\">",
"     23",
"    </a>",
"    ]. In azole exposed patients, increasing the dose of the azole alone is unlikely to be successful. In such cases",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily) should be administered until CSF, blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other sites are sterile.",
"   </p>",
"   <p>",
"    After induction therapy, pending in vitro susceptibility testing, salvage consolidation therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (800 to 1200 mg orally daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (200 to 400 mg orally twice daily), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    (200 mg orally four times daily or 400 mg orally twice daily) for 10 to 12 weeks can be administered. If the isolate is found to be susceptible to fluconazole, therapy with this agent may be reinstituted. There are no data regarding voriconazole and posaconazole as primary treatment of cryptococcal meningoencephalitis but they have been used as salvage therapy for HIV-infected individuals in open trials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Among 18 patients with refractory disease treated with voriconazole, 39 percent had successful treatment and 55 percent had stabilization of disease. Among 29 patients with refractory disease treated with posaconazole, 48 percent had successful treatment and 20 percent had stabilization of disease.",
"   </p>",
"   <p>",
"    The use of INF-gamma as adjunctive therapy during primary (not salvage) treatment has been evaluated and its efficacy was not definitive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/26\">",
"     26",
"    </a>",
"    ]. It may be a reasonable consideration in refractory cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cryptococcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral cryptococcomas can cause significant morbidity, are difficult to treat, and require prolonged antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. They are more common in the setting of C. gattii infection than C. neoformans infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/14,27,29\">",
"     14,27,29",
"    </a>",
"    ]. Severely immunosuppressed patients may have masses due to other causes besides Cryptococcus, and those that do not respond to therapy should undergo biopsy or aspiration.",
"   </p>",
"   <p>",
"    There are no prospective studies evaluating management of cerebral cryptococcomas; the approach to therapy is extrapolated from observational studies, literature addressing management of cryptococcal meningitis, and expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/28,30-32\">",
"     28,30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Induction therapy for cerebral cryptococcoma should consist of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (0.7 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally in four divided doses) for at least six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. Consolidation and maintenance therapy for cerebral cryptococcoma consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 to 800 mg orally daily) for 6 to 18 months.",
"   </p>",
"   <p>",
"    The duration of therapy depends on the clinical and radiographic response. Some brain lesions persist radiographically for long periods",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    develop surrounding edema during effective antifungal therapy, presumably because of an immunological response associated with control of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/33\">",
"     33",
"    </a>",
"    ]. Prolonged therapy and repeated induction courses may be warranted in some cases, even when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is used for consolidation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoids may be administered in the setting of mass effect and surrounding edema, especially if there are neurologic deficits. If glucocorticoids are used the doses should be tapered gradually to prevent \"rebound\" IRIS (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Immune reconstitution inflammatory syndrome'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Surgical removal (open or stereotactic guided) may be necessary for large (&ge;3 cm) lesions and lesions with mass effect with substantial surrounding edema. Surgery may also be needed in the setting of optic nerve involvement and in cases unresponsive to prolonged or repeated induction antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/28,33,34\">",
"     28,33,34",
"    </a>",
"    ]. Shunting is indicated for symptomatic hydrocephalus with dilated cerebral ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/35\">",
"     35",
"    </a>",
"    ]. All surgical specimens, particularly enlarging lesions not explained by immune reconstitution inflammatory syndrome, should be submitted for histopathologic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunologic alterations associated with pregnancy may increase the severity of cryptococcosis in pregnant women; the mortality rate approaches 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of pregnant women with CNS or disseminated disease consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (0.7 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily) or a lipid formulation of amphotericin B (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    [3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    [5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily]) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. Amphotericin B deoxycholate (pregnancy category B) is well distributed in the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/37\">",
"     37",
"    </a>",
"    ]. The optimal duration is not certain; an induction regimen similar to that for CNS disease in non-HIV infected, nontransplant hosts is reasonable, and duration should be tailored to trimester of treatment initiation to ensure antifungal drug treatment throughout pregnancy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     Flucytosine",
"    </a>",
"    (pregnancy category C) has been used to treat cryptococcosis in the second and third trimesters and has not been associated with adverse outcomes, although the literature is limited to case series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/38\">",
"     38",
"    </a>",
"    ]. Its use during pregnancy should be determined on an individual basis; it may be administered after delivery.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    (pregnancy category C) should be avoided during the first trimester; it has been associated with birth defects [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The risk of fluconazole use in later pregnancy should be weighed against the need for antifungal therapy during pregnancy. In some circumstances it may be appropriate to administer fluconazole during the second and third trimesters to ensure continuous antifungal therapy.",
"   </p>",
"   <p>",
"    Immune reconstitution inflammatory syndrome can occur in the postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Indeed, nearly half of the Cryptococcus cases reported in pregnancy presented with symptomatic disease in the third trimester or postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Immune reconstitution inflammatory syndrome'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcus has been reported in children with primary immunodeficiencies such as hyper-immunoglobulin M syndrome and severe combined immunodeficiency syndrome, as well as in children with HIV, connective tissue diseases, and solid organ transplant recipients. Cryptococcosis has also been described in children with no recognized immunodeficiency.",
"   </p>",
"   <p>",
"    Treatment of children with CNS or disseminated disease consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally per day in four divided doses) for two weeks, followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (10 to 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally per day) for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. Alternatively, amphotericin B and flucytosine can be administered for 6 to 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/43\">",
"     43",
"    </a>",
"    ]. In the setting of amphotericin B deoxycholate intolerance, lipid formulations of amphotericin B (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    [5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    [5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily]) may be substituted. Maintenance therapy is fluconazole (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally daily).",
"   </p>",
"   <p>",
"    Literature concerning pediatric cryptococcosis is limited to small series; therapy is based on extrapolation of studies in adults. The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate ranges from 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily; children generally tolerate this agent better than adults and a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day is commonly used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/44\">",
"     44",
"    </a>",
"    ]. Successful treatment of Cryptococcus in children using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    has been reported at daily doses of 5 to 7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     Flucytosine",
"    </a>",
"    can cause myelosuppression; monitoring of flucytosine levels and blood counts should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/47\">",
"     47",
"    </a>",
"    ]. The American Academy of Pediatrics suggests that flucytosine concentrations should be maintained between 40 and 60",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/43\">",
"     43",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    dosing is higher in children than adults since the volume of distribution is larger and the clearance is more rapid [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INTRACRANIAL PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of intracranial pressure is one of the most critical determinants of outcome for cryptococcal meningoencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/13,50\">",
"     13,50",
"    </a>",
"    ]. The intracranial pressure should be measured at the time of initial lumbar puncture. If the pressure is &ge;25 cm of CSF and there are symptoms of increased intracranial pressure during induction therapy, CSF drainage should be performed to reduce the pressure by 50 percent (if extremely high) or to a normal pressure of &le;20 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach is extrapolated from literature describing HIV patients with cryptococcal meningoencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/50\">",
"     50",
"    </a>",
"    ]. Among 55 patients with CSF pressure &gt;35 cm, increased incidence of papilledema (29 percent) and impaired mentation (18 percent) were observed. Among 12 patients who died in the first two weeks of therapy, 91 percent had baseline intracranial pressure &ge;25 cm. Among the 161 patients treated by CSF lumbar drainage to reduce the pressure there were fewer cases of clinical failure and patients reported relief of severe headache; recurrence of elevated pressure was associated with worsening symptoms.",
"   </p>",
"   <p>",
"    Therapeutic lumbar drainage should be repeated daily in the setting of clinical symptoms and persistent pressure elevation &ge;25 cm of CSF, until stabilized for &gt;2 days. Temporary percutaneous lumbar drains or ventriculostomy may be appropriate for patients who require repeated lumbar punctures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/35,51\">",
"     35,51",
"    </a>",
"    ]. Ventriculoperitoneal shunting may be warranted if the patient is receiving appropriate antifungal therapy and more conservative measures to control increased intracranial pressure have failed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/35,52,53\">",
"     35,52,53",
"    </a>",
"    ]. In one series of 27 patients with obstructive hydrocephalus and cryptococcal meningoencephalitis, 63 percent had good outcomes following permanent shunt placement; outcomes were worse in those with Glasgow coma score &lt;9 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    are not appropriate agents for control of elevated intracranial pressure in the setting of cryptococcal meningoencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/54\">",
"     54",
"    </a>",
"    ]. There is no benefit to administration of glucocorticoids, except in the setting of immune reconstitution inflammatory syndrome (IRIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Immune reconstitution inflammatory syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MODULATING IMMUNOSUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive regimens frequently include a calcineurin inhibitor (eg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ; the drug-drug interactions and adverse effects associated with these agents must be considered carefully in the setting of cryptococcal infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reduction in immunosuppressive therapy may be beneficial for control of cryptococcal infection, although this must be balanced with the potential for organ rejection and immune reconstitution [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Immune reconstitution inflammatory syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The optimal approach to management of the immunosuppressive regimen in organ transplant recipients with cryptococcosis is uncertain. Spacing the reduction of immunosuppressants over time in a step-wise fashion following initiation of antifungal therapy is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/21\">",
"     21",
"    </a>",
"    ]. It may be helpful to reduce corticosteroids before calcineurin inhibitors since the latter class has direct anticryptococcal activity in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Immune reconstitution inflammatory syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune reconstitution inflammatory syndrome (IRIS) refers to paradoxical worsening of an infectious process following restitution of immune function. IRIS occurs most commonly in HIV-infected patients with initiation of antiretroviral therapy, although it has also been described in solid organ transplant recipients and apparently healthy hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/14,55,58,59\">",
"     14,55,58,59",
"    </a>",
"    ]. In one study of 83 solid organ transplant recipients with cryptococcosis, 5 percent developed signs and symptoms suggestive of IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/55\">",
"     55",
"    </a>",
"    ]. Transplant recipients who develop IRIS are more likely to have received a potent immunosuppressive regimen (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) than those who do not develop IRIS. Presence of cerebral lesions is not predictive of subsequent IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Onset of IRIS in solid organ transplant recipients has been described a mean of six weeks after initiation of antifungal therapy. Manifestations may include fever, lymphadenitis, and signs and symptoms of meningitis. ARDS can also be a symptom of IRIS in immunocompromised individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distinguishing between IRIS, relapse or progression of cryptococcal infection, and other infections or complications can be difficult in severely immunocompromised individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Clinical manifestations, inflammatory CSF values and positive India ink exams may be present in both IRIS and cryptococcal infection. The most important distinguishing feature is that patients with active infection have positive CSF cultures, whereas patients with IRIS have sterile CSF cultures.",
"   </p>",
"   <p>",
"    Patients with IRIS should continue antifungal therapy. Those with minor manifestations can be managed with supportive care; symptoms frequently resolve spontaneously in days to weeks. In the setting of CNS inflammation with increased intracranial pressure, oral glucocorticoids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily) may be used, although no trials have been performed to prove the benefit of this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"     1",
"    </a>",
"    ]. For severe cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    may be used. Glucocorticoids may be tapered over two to six weeks, depending on clinical circumstances. The course should be given with concomitant antifungal therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link&amp;anchor=H23#H23\">",
"     \"Immune reconstitution inflammatory syndrome\", section on 'Role of anti-inflammatory agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important prognostic factor is the nature of underlying immunosuppression. Prognosis among patients with malignancy is much worse than among those with immunosuppression related to glucocorticoid therapy or those with no apparent risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/31\">",
"     31",
"    </a>",
"    ]. In one study of patients with cryptococcal meningoencephalitis, patients with malignancy had a shorter median survival rate than those with HIV infection (two versus nine months) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/61\">",
"     61",
"    </a>",
"    ]. Relapse rates among solid organ transplant recipients are very low [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors conferring poor prognosis include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/54/15210/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Positive India ink examination of the CSF",
"     </li>",
"     <li>",
"      CSF white blood cell count",
"      <span class=\"nowrap\">",
"       &lt;20/microL",
"      </span>",
"     </li>",
"     <li>",
"      Initial CSF or serum cryptococcal antigen titer &gt;1:32",
"     </li>",
"     <li>",
"      High opening pressure on lumbar puncture",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of cryptococcal meningoencephalitis consists of antifungal therapy, management of intracranial pressure and reducing immunosuppressive therapy. The choice of the antifungal regimen varies depending on the nature of the host and extent of disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites or cryptococcal antigen titer &ge;1:512) should be managed as for central nervous system disease, even in the setting of normal findings on spinal fluid examination. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that organ transplant recipients with cryptococcal meningoencephalitis receive induction therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest lipid formulation amphotericin agents over amphotericin B deoxycholate (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Dosing is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (3 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"       amphotericin B lipid complex",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) plus flucytosine (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally in four divided doses, adjusted for renal function) for at least two weeks (",
"      <a class=\"graphic graphic_table graphicRef56336 \" href=\"UTD.htm?42/59/43963\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that non-HIV infected, non-transplant hosts with cryptococcal meningoencephalitis receive induction therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef77297 \" href=\"UTD.htm?25/61/26588\">",
"       table 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Dosing is amphotericin B deoxycholate (0.7 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) plus flucytosine (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally in four divided doses) for at least four weeks; a two week induction period of combination therapy is appropriate for patients with good responses and prognosis. In patients with renal insufficiency,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (3 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"       amphotericin B lipid complex",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) may be substituted for amphotericin B. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who present with positive baseline CSF cultures, severe symptoms, or significant underlying immunosuppression should undergo repeat lumbar puncture after two weeks of induction therapy; lumbar puncture may be repeated sooner for management of increased intracranial pressure or concern about potential microbiologic failure. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients whose cerebrospinal fluid (CSF) cultures remain positive despite two weeks of induction therapy should continue the induction regimen with serial lumbar punctures every two weeks until the CSF becomes sterile. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend consolidation and maintenance therapy following induction (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest that consolidation therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 to 800 mg [6 to 12",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      per day orally) for eight weeks be administered, followed by maintenance therapy with fluconazole (200 to 400 mg per day orally) for 6 to 12 months (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Consolidation and maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Distinguishing between persistent or relapsed cryptococcal infection, immune reconstitution inflammatory syndrome (IRIS) and other infections or complications can be difficult in severely immunocompromised individuals. Patients with active infection have positive CSF cultures, whereas patients with IRIS have sterile CSF cultures. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Persistent or relapsed infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that non-HIV-infected, non-transplant hosts with cerebral cryptococcoma receive induction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"       amphotericin B lipid complex",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Dosing is amphotericin B deoxycholate (0.7 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily), liposomal amphotericin B (3 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) or amphotericin B lipid complex (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) plus flucytosine (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally in four divided doses, adjusted for renal function) for at least six weeks. We suggest consolidation and maintenance therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Dosing is fluconazole (400 to 800 mg per day orally) for 6 to 18 months. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cryptococcoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Control of intracranial pressure is one of the most critical determinants of outcome for cryptococcal meningoencephalitis. The intracranial pressure should be measured at the time of initial lumbar puncture. If the pressure is &ge;25 cm of CSF and there are symptoms of increased intracranial pressure during induction therapy, CSF drainage should be performed to reduce the pressure by 50 percent (if extremely high) or to a normal pressure of &le;20 cm. Therapeutic lumbar drainage should be repeated daily in the setting of clinical symptoms and persistent pressure elevation &ge;25 cm, until stabilized for &gt;2 days. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Intracranial pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reduction in immunosuppressive therapy may be beneficial for control of cryptococcal infection, although this must be balanced with the potential for organ rejection and immune reconstitution. Spacing the reduction of immunosuppressants over time in a step-wise fashion following initiation of antifungal therapy is appropriate. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Modulating immunosuppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Onset of immune reconstitution inflammatory syndrome (IRIS) in solid organ transplant recipients with cryptococcal meningoencephalitis has been described a mean of six weeks after initiation of antifungal therapy. Manifestations may include fever, lymphadenitis and signs and symptoms of meningitis. Patients with IRIS should continue antifungal therapy. Those with minor manifestations can be managed with supportive care. In the setting of CNS inflammation with increased intracranial pressure, glucocorticoids may be used. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Immune reconstitution inflammatory syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/1\">",
"      Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/2\">",
"      Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008; 47:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/3\">",
"      Sun HY, Alexander BD, Lortholary O, et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 2009; 49:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/4\">",
"      Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis 2005; 40 Suppl 6:S409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/5\">",
"      Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/6\">",
"      van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/7\">",
"      Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013; 368:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/8\">",
"      Dromer F, Mathoulin-P&eacute;lissier S, Launay O, et al. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007; 4:e21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/9\">",
"      Dromer F, Bernede-Bauduin C, Guillemot D, et al. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One 2008; 3:e2870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/10\">",
"      Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis 2010; 51:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/11\">",
"      Singh N, Lortholary O, Alexander BD, et al. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation 2005; 80:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/12\">",
"      Igel HJ, Bolande RP. Humoral defense mechanisms in cryptococcosis: substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans. J Infect Dis 1966; 116:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/13\">",
"      Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987; 317:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/14\">",
"      Ecevit IZ, Clancy CJ, Schmalfuss IM, Nguyen MH. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis 2006; 42:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/15\">",
"      Zonios DI, Falloon J, Huang CY, et al. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore) 2007; 86:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/16\">",
"      Rex JH, Larsen RA, Dismukes WE, et al. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) 1993; 72:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/17\">",
"      Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994; 19:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/18\">",
"      Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998; 26:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/19\">",
"      Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008; 46:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/20\">",
"      Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med 1974; 80:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/21\">",
"      Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007; 7:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/22\">",
"      Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/23\">",
"      Witt MD, Lewis RJ, Larsen RA, et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 1996; 22:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/24\">",
"      Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/25\">",
"      Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/26\">",
"      Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/27\">",
"      Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/28\">",
"      Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/29\">",
"      Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 2000; 31:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/30\">",
"      Waterston JA, Gilligan BS. Cryptococcal infections of the central nervous system: a ten year experience. Clin Exp Neurol 1987; 23:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/31\">",
"      Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/32\">",
"      Brouwer AE, Siddiqui AA, Kester MI, et al. Immune dysfunction in HIV-seronegative, Cryptococcus gattii meningitis. J Infect 2007; 54:e165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/33\">",
"      Hospenthal DR, Bennett JE. Persistence of cryptococcomas on neuroimaging. Clin Infect Dis 2000; 31:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/34\">",
"      Blackie JD, Danta G, Sorrell T, Collignon P. Ophthalmological complications of cryptococcal meningitis. Clin Exp Neurol 1985; 21:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/35\">",
"      Park MK, Hospenthal DR, Bennett JE. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis 1999; 28:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/36\">",
"      Ely EW, Peacock JE Jr, Haponik EF, Washburn RG. Cryptococcal pneumonia complicating pregnancy. Medicine (Baltimore) 1998; 77:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/37\">",
"      Dean JL, Wolf JE, Ranzini AC, Laughlin MA. Use of amphotericin B during pregnancy: case report and review. Clin Infect Dis 1994; 18:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/38\">",
"      King CT, Rogers PD, Cleary JD, Chapman SW. Antifungal therapy during pregnancy. Clin Infect Dis 1998; 27:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/39\">",
"      Tiboni GM. Second branchial arch anomalies induced by fluconazole, a bis-triazole antifungal agent, in cultured mouse embryos. Res Commun Chem Pathol Pharmacol 1993; 79:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/40\">",
"      Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/41\">",
"      Annapureddy SR, Masterson SW, David HG, Greig JR. Post partum osteomyelitis due to Cryptococcus neoformans. Scand J Infect Dis 2007; 39:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/42\">",
"      Singh N, Perfect JR. Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis 2007; 45:1192.",
"     </a>",
"    </li>",
"    <li>",
"     Cryptococcus neoformans infections (cryptococcosis). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.294.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/44\">",
"      Gonzalez CE, Shetty D, Lewis LL, et al. Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/45\">",
"      Manfredi R, Coronado OV, Mastroianni A, Chiodo F. Liposomal amphotericin B and recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in the treatment of paediatric AIDS-related cryptococcosis. Int J STD AIDS 1997; 8:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/46\">",
"      Athanassiadou F, Tragiannidis A, Papageorgiou T, Velegraki A. Fungal brain abscesses in leukemia. Indian Pediatr 2006; 43:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/47\">",
"      Soltani M, Tobin CM, Bowker KE, et al. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents 2006; 28:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/48\">",
"      Lee JW, Seibel NL, Amantea M, et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/49\">",
"      Seay RE, Larson TA, Toscano JP, et al. Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases. Pharmacotherapy 1995; 15:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/50\">",
"      Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000; 30:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/51\">",
"      Macsween KF, Bicanic T, Brouwer AE, et al. Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. J Infect 2005; 51:e221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/52\">",
"      Pappas PG. Managing cryptococcal meningitis is about handling the pressure. Clin Infect Dis 2005; 40:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/53\">",
"      Woodworth GF, McGirt MJ, Williams MA, Rigamonti D. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis. Surg Neurol 2005; 63:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/54\">",
"      Newton PN, Thai le H, Tip NQ, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002; 35:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/55\">",
"      Singh N, Lortholary O, Alexander BD, et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005; 40:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/56\">",
"      Kontoyiannis DP, Lewis RE, Alexander BD, et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 2008; 52:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/57\">",
"      Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/58\">",
"      Ingram PR, Howman R, Leahy MF, Dyer JR. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis 2007; 44:e115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/59\">",
"      Sun HY, Singh N. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin Infect Dis 2011; 53:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/60\">",
"      Charlier C, Dromer F, L&eacute;v&ecirc;que C, et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One 2008; 3:e1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/54/15210/abstract/61\">",
"      White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992; 165:960.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2443 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15210=[""].join("\n");
var outline_f14_54_15210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIFUNGAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Induction therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2294041\">",
"      Repeat lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Consolidation and maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Non-HIV infected, nontransplant hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Induction therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Consolidation and maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Limited drug tolerance or availability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Persistent or relapsed infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cryptococcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INTRACRANIAL PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MODULATING IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2443\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2443|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/59/43963\" title=\"table 1\">",
"      RX crypto mening transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/61/26588\" title=\"table 2\">",
"      Rx crypto mening non-HIV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=related_link\">",
"      Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=related_link\">",
"      Cryptococcal infection outside the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43190?source=related_link\">",
"      Pharmacology of flucytosine (5-FC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23929?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_54_15211="Incidence of intracranial hemorrhage by mode of delivery";
var content_f14_54_15211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of intracranial hemorrhage by mode of delivery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Delivery type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vacuum extraction",
"       </td>",
"       <td>",
"        1 in 860",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forceps",
"       </td>",
"       <td>",
"        1 in 664",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forceps and vacuum",
"       </td>",
"       <td>",
"        1 in 280",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cesarean delivery after failed forceps/vacuum",
"       </td>",
"       <td>",
"        1 in 333",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cesarean delivery with labor",
"       </td>",
"       <td>",
"        1 in 907",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cesarean delivery without labor",
"       </td>",
"       <td>",
"        1 in 2750",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous vaginal birth",
"       </td>",
"       <td>",
"        1 in 1900",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: data in Towner D, Castro MA, Eby-Wilkens E, Gilbert WM. N Engl J Med 1999; 341:1709.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15211=[""].join("\n");
var outline_f14_54_15211=null;
var title_f14_54_15212="Air embolism lab findings";
var content_f14_54_15212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory findings associated with air emboli",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Electrocardiographic changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinus tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right heart strain (peaked P-wave)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-specific ST-segment and T-wave changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute myocardial ischemia or infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Radiographic findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal (most common finding)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other findings rarely reported include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Air in the main pulmonary artery*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Focal oligemia (especially upper lobes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pulmonary artery enlargement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atelectasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intracardiac air",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Air in the hepatic circulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Arterial blood gas abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxemia (may be severe)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercarbia (increased dead space)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hemodynamic changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increase in central venous pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increase in pulmonary artery pressures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increase in right ventricular pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fall in cardiac output",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fall in mean arterial pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Serological findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fall in platelet count",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Although this finding is only rarely reported, it is pathognomonic for air embolism.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15212=[""].join("\n");
var outline_f14_54_15212=null;
var title_f14_54_15213="TNM staging RCC";
var content_f14_54_15213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for kidney cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Tumor 7 cm or less in greatest dimension, limited to the kidney",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor 4 cm or less in greatest dimension, limited to the kidney",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor more than 4 cm but not more than 7 cm in greatest dimension, and limited to the kidney",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T2",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Tumor more than 7 cm in greatest dimension, limited to the kidney",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T2a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor more than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T2b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor more than 10 cm, limited to the kidney",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T3",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Tumor extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond Gerota's fascia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T3a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor grossly extends into the renal vein or its segmental (muscle containing) branches, or tumor invades perirenal and/or renal sinus fat but not beyond Gerota's fascia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T3b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor grossly extends into the vena cava below the diaphragm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T3c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor grossly extends into the vena cava above the diaphragm or invades the wall of the vena cava",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in regional lymph node(s)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       MI",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage III",
"      </td>",
"      <td>",
"       T1 or T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0 or N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IV",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15213=[""].join("\n");
var outline_f14_54_15213=null;
var title_f14_54_15214="Effects of dynamic intrathoracic airway obstruction";
var content_f14_54_15214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effects of dynamic intrathoracic airway obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 266px; background-image: url(data:image/gif;base64,R0lGODlhRwEKAfcAAP////+Zmf//mQAAAP8AAJ9fX++Pj9+Ghp+fn9/f3185Oc98fL9zc7+/v8/PfJ+fX39MTO/vj19fOe/v719aWnd3d4hSUg8OCS8uHBEREVVVVY9WVp9jX19AOYiIiC8jHM/PzzMzM29DQw8NCe7u7j8mJv//zN/fhi8eHq9paczMzA8MDE8vLz83N6qqqh8YGI+Lix8WFq+vr398fIiIUh8ZGd2FhV9VVQ8KCn91dS8nJx8UFC8oKA8LCy8fH4+Pj29qak9HR0QpKT8/JiIiIn95eQ8MCURERD8nJ5mZmV8+Od3d3X9/TD81NWY9PTMfH+6Pj09FRSIUFEREKR8eEz85OW9kZG9vQ09JSbu7cL+/cy8mJv9fX2ZmZj8pKf8/P29mZv8TE/+fn//f3//Pz19YWP8mJh8YEz8yMi8pKR8TE39PTJlcXJ+bm8x6ei8iHA8PCW9IQ7u7u08xMf8PD//v7/+GhpmZXG9FQ19YOTMzH29pQ/9/f/8JCf98fP9paf9DQz8/P/+Pjw8LCd3dha+rqw8KCT8qJj8zM/8vLw8PCz85Jh8XE/9zc39ycn9/f+7ujz82JgkJBg8PD1VVM4+PVszMeo9ZVk85L7twcKpmZj8sJj8qKg0NCU81L/+/v19fX8LCwmZmPU9PLxISC1UzMyIiFK+vaXRPT09NL3d3R0tLLeW1tRERCjAnHaqqZk80MAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABHAQoBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXct2ZoUBcOG6eKhiQAaHLuwK9DBAQ1uBGeLetahhgAeHIQwDHqDir8G3fkfmHeyY4NsKKRMfrowQsuW+APKGIAH3CFzMde++PWKaRGK4IVTUjVuBr18She0mCW23C9zNXy8LTKwh8WgASYjEVfE2hHIiSwAU9kB6wOW8tKXHHUAicOPkpUkA/yBuXDzZt9vFF1YRIsOS6i5IKJeTGgB6uOYB8CXCe7Dt8Yol5sJkJEwWlnAAYqZZavk1p98AR2hH3XaYCSTfALtptpgKefGXxAAhJAggcGJ5VlAIickBQHWNTVeficiZBtddBj6owRJwRfdWFwbOll9XCGpYWAU42lXBbp7VNx2LFt4XoGIAeOdbFyvmKKR1ZcFoIRECVskYAKZ58CJoAMhhF4d61WhbkToOwKNePoIVpGJDhlZBYBh6ZuZdS8LVGJigaahhlIxN6eUSV1Y4lpaAIuoei0t4N2ZkBvJ11557BfrkgHDiJyeWI2qnKADKJeGZb371+eWIFx4W5oYdIv8HYqh1nrfdAC54Jlp1ymWw26QDyZjYYDLWBhpuM+7Wo6de4alXotj9Zt8AykGonmFMhhYYEcod5gKe3X0JnrW0gspZtpy1xGi6KaHLrkrrvivvvPTWa++9+Oar77789uvvvwAH3FEDAhesUwIDJGBwRgMsvNEjAzzi8EUNT4zRJANMYnFFFW9MEQJxIeCxRB2PHFEgcQViMkQlr9wQCLeC4HJDLc+sECi3gmLzQjXvbNAEAwQCMgIoT+AzQj0fPVACMgNQMQgKK11Q0lITRLXUV1s8gAlcd+2111uDvXHYX5dtAtlcZx3wAAK07fbbb7Md99hw1+223HebjLfdccP/rXa/e/PdduB//xu44ITTLXjfc498ON+Ja70443k7Pvndfit+eeQeP2435w57Xjfokl8uAOkGi+535pabjnrBqlM+uN6mn876xLFj3njntb8ucO6D36755L6vvfrnwpe+efKpHz8686HbrcXzu0cv+/WF+3v4CQOc4PzsygePfPXht83EAEx8f/rwto9fOe9wwzEAHOpnry/hkEO/cOAPxPUA9uzzXPFgB7chxGUIACyfAPXXPLc54FYO0N37rCfB+tHObRK4lQQquD4F5o98uHNbBAYwhP49wIAREN8E96c+DtqPX3g7QQTb5wDvtW+FDeSgCy/YwgEaroUqBB/8/3rIQIDhz31CZF8Ql/hCfB2Rejik4PVumEQWTpGJPJyiD7UHRCp2cIhaLOIPr+jFJt4PiVj0IBrNmK/HHW6LgOsiHMdIRBASkIxz5CIUd6jGPX5RiV4sYwA/GEUr1rGQxsOjGBN5yCrmcIl8BKMO83hGRdrRkGG8JCMhmUZJQpKSbZTjIo2IRkH20YKta+QfMRnITgLyjaOEoSg1eUdVsrFeT0SlJwMJSifOEpG1zCQw6chJU+4SlrQkZiuN+Uo/3pJeuUzgMZ05yDVmcZKx3FcuZSi+Gq4yhH5kJiv3NsISDuCEA0jhM+3lRmqeUgAZ3M4GvylFHY6umg6EoCPrWf/MZOpRhwaECwL3ycp+DvOfkOwfXP5H0EfaM5uVtKf86HdQUobznu80H/r8adEuclSWV+SeDRsazId+VJtdnN5J43hRiIaSjBidJvHwOdNUwrSiIDWpS1Ha0pW+VKc+5alHcSpUgwY1ojclqTKBR8+CLvOo7BwqVH3ZU6Ii9ak7ZQvIeAAEGRhNIe2saUImIAMg8CAuFIhaWRJAgQFEAQFfTUg0EbcQspoVrWpda1s3kAIRoGAAaZVrKWN6kBkMAAUiSIEBAnAABQxAZGNh6wAUsIACzAGweZ2aVIFpWMQqlrGOhSxZQKaAAwTgtKDF7EHCurikgSANKFgAamdbgMf/ioW0pkVtY1VrkLlCDiGvje1sUVtb0YYFZAUYrm4d2zSrDRZ6IIOAcmk7gOZ2BbnTTa11BeLbzx0kutk9bW232xXDJje8AdhADeLK3eeCELvoDQAEdPAV88ZXvex1mgC4ScORercg8EXvfMESXNnGNwAswIJmq1rFAMcXBUXgSoEPjGAFO7ecJkRhawE8gPMeGMJegZl0KRwAA+wABs5l8B9h5uEDL6C6WhExiUt84hTHMy7zpOtAWDzjF5PXKhPQwQZmfNoXq5W1OgbABGowZCIXYAWZnUqQm9zjhA1Ebg/czgyTvGQqk/jJUa4KGJBAZNQqgAJXdu/7sMCCMp9W/wQ8yK9UxuzmAJw5zW0LKAk3NxA21xnOcp6KDHCwWDcfwMr6rR3rYLCDQrs5wVYZtKOJfOio4U2h5+QzABg9aSJD+ioTWEEK6nzaOyda0XlDmIHrbAAUAIEqoR41qU29t4m6DgCqJnWJXX2VKohA14y1LVPvSQEFAJuxOGjDVHwN7EOLbG/nSx+fi33sAyS7KjBAQafdXNxh+w1huQW2j6OS7W2XudtvE6nrwH3sAIxbKjBbNbBr6+24Ubvd8m0BVOKNb3rDTaWbu3e7IaBvqbRgxP2u990GEO5jmxjFTjk4vsWr8MExfOIPJ3ejJ37aip8O4fhmwAoCbRROczwAHv8fAMjbLXKSHyXUDDg5ylEdN5lXmCkwl3nKbf7ppvhZ5zS/m80NgAOCKeXnJ9+5zIlu9KU0gNA2V7rM8ZuUp5v72FI/OdWV0mWbzzzop/N6AJAQ4Zcz2etZPznZl1IEMqMd7GH3upGP0naxp53jc0dKrt8O9gGI3c5oLsreow53v4vd1EcJwq/tXvi/V7ooiv/73Tn+eKNYXfKN/zvig3J5xvf974A/ShNWDvTPOx7RQRk96CdPedQLpQ07AP3Xg254zQceKLCXPes5vvmgvKDFfKe97Cv/k9/rPvOnDzNPZuD21SPf9kBhvuxnT/PaQz8oE+hBzHXPUFT3b/rE30n/9re/+u4r+vvDd31PgNDm6aN8AJHYw5b55oA9uAIu7u89TeowhoGw3/21JQH+NTn9A3yHd3tjUAfid3ET5wfxdQApoACGsAgD2DYnsAiGoAAp0HDD5YCtp3wuQQZcQABkIBBAw4GOpwSZNjknkEEGKHaVRwYEwAUliBMw0H4TlwhhwAWCEF8GIAKDMH8C4ACDIAJXFwCCwAVhkAgyp38uIQZfQAAE8AUDcYPuR10VmG4DoAQoCHqIF4VTKAY3wQMvqGuNIIV9AAh2EF8FYAQjdQJGUIYBYAeA0AdS2AgyF34sMQZ8QAdSKIViKBBkeIWzpQQ5ZjcSAAuEqFuIJgZ//0gAdMAH/ScTCdADNhcGj2gGf4BeCpAHbpMHxjZdf2AGjxgGXueEKPEJj7iKrNiKrviKsCiFs/VirSVvsXiLuJiLBPAJI6GLvviLrGgG4bUARuA2RiBvqEWKwLiMvxgSfOiHfxiIQBCKixgABZAKi7MKcgh6j+eIfxiJkxgTNUB+HIeJf6iJ8YU31jdco1iKBygTUCiFVAgA41iNp4UJ5lc3D4AJ9lhqaAaGXxCIM9EAsSdzZ0gAabiG8UWMxoiMw0WHdkgAeGhzehiCI0gGBNmPtZVCgjNC23h6rDCDNVgTZbB4J6eDPEhinfiJ1BheSbiE77h/Y1CS9lhb+Wg3Bf/YjwqACgqIEyvQhcfmgV/mhm4Dhx+JWkKZh+oXEz9ZjTZZO/3DhdVYkTKBACjQj6j1g0EIN0RohFjpjzVhlU65grXTguuYf7dXE1HgZYQIgRJIgXZzgRm4gf14aC63EmtZjWSJamcJfgNwlyyBMEcoefAnf5NTf5GAf/bIAhAXE4Kpl89HiIxpEzOAg4S4e6BXADwwE5Vpj5j5d5ppEzUga4v4mX/XAyCYEqPpmZFJiKhJEzJQkJBpevaoAK8GE7HZj6Z5eLcpE0FAeu63m17HADUQE7+pm615hcQ5E+zGmrRpjzvQdIHJgLMpfFgZnTLRmcj5nNUoAmXwEtrpnNb/2Y/eKROruZ3jaY8HsAIvcZ7iSQNxoQeEQDxfuZ4xkZtYuTfbQQP0+ZUoYFwpgZ/oSQNT0DZTQAn9iZX/CRPHmZ9xkwUCkAUDYAmt9ZXpFQUt0aADWqACcAemkKDoZQFx8QQ2wHEbgKEucYJfqZ8QKgCmcAcVGl8iChckenIGsE4VoaIO2jYEKgCQoAeiAKI2wAbTZQFCcFpCUAocd6MvIQNXuaIP2qEDMJ+IE15sAAUBYKRIqqQn5wPSeRJOaqF4A59wMQWQIKRPIAUWMFxaGgBsIAVd+qUpUQbAeZlxAxetAKMxyqZS8ARY2qZv2oQ/sBJ0KqZu06MwdZZu4AQD/+AEJZqlRwoFT+AEymUBa1pnCjCoLVGPUHo3Lcqj/Pk5s2UDjOoEboBaWiqplMqml1pnG3ADK8GpOyoAiNo2olCmNEADesChcTddcJEJWRoXQoClrEpqr9oSlWih1DcAn0oIcSGhr8Csg4NamTAAcMqmwkqss2WpusYA9JUSyWqoPMqr4qOrVDqtw7WojfqobZpd3Fpn3toSP2CZ6Hk6n0qroToAoYqup0WqjXqqp9WuRdqqdYajEjGvyqo6cpOrfjOqaUqwkDqqA/AEEwsF71qwLZGX4so3DFtGRdqnf3qkqGUDE1uxF1tnXpoSGtupkHOmHSt0I0uklSqy/ToAp/+qpidbZim7Ek25sXZDA6rARFYashJ7s5YKsWWWqSnRsyxrN5QwAFPwsvxKZCR7Wk5wtLqmtCrRADGgrNRXN5YAFxLasGVWtQFwtTlbZsd6ElzrtcI5XFULBVKgCWk7Y2ubEkXQkrNafW4Wt3NbtzMWryeRt26bnAdGsnBxpIBLYYKbEjxAmk3Ll30rrFmKtGVmsA/xuIXLnSRmthOHuRExAIN5hW87sn0JbDtbEqK7uek5Y56Lb6lrEg3gA177tYp2uuj1uvjGAgAaErNbu6X7d7ybEghAr/3IASnHAV4LAVZgEsXrtchbeMqrrMybElZQp4TIARdwk1B5AdP7lQz/0AQmcb3Kqr3cazoP4L3KGr4p0QTkaI/aK4Q05wDqW5/sWRLua6HxC3dtQ7/fW5f3exJMC78XIL9B578W+pokMcDVuL/827/1i5UKXBLherwF/MBvg8BYiQRy6hEVTMAGDHYa3I8czLbN18AXjMEZHMHdWXYi0QAnvIgOrMIQ/L+LKAIuTBJFYJKLiAcpTMMOdAF4oJFBoMM8TIg+HMIPTL9DXJNFbBJBcJQ21wE/DMRB3AH2yABbQBJRbI9UrMQYTL9YXI1afBJb8L7T1wFUAMZxiWoOQAVjXJokccbVqMZsXDdZKDhvHMeXeRK4K3YdgAEceX57eTkRgAF87H4x/9DBHPHHXhfIgwyVhTw5h5zI07fIJdG2hAjJNPcAioAAinC+fFPJi1gCvcsRmnyFnOx9nxzKqEbKhGjKJYEAJbDJgkxzV9AJMgMCkiDKdgPL7gcBOSAStGzLkWw6ubzLvfzKiEyIwlwSOYC9MrfKiiYBpBAKVzYCV8DMlix2BVBwIBHNqnzLqGbN2Mxd2szNV/jNJdECUuxwh0DOtRMBo/ABJTMAC3AGh2jIGHAIoxtyLyAS7jx9BhDPx0zJ9XzP+bzPlNzP/8xyAU0SL4DGS/cB8mw6h7wJTHplJfYBDL04h/wBD411IjHRsmcAFn3QII0BGn3PHf3RHYkBIj19oP8LVif9AUOg0oJzAs2MclZzWigtATr9y0Mw06CHySDhyO2G0jmNajw9xi790kNdNxFQ1COta0jtu137d0E9vxcQx1Hd0Rd9ORJg1GInyx+Ryl7X1W781agV1ig91pNT1lddZ2gdEsUsdmytaPR7CbNVMnQM1NRsOnT9d8/8EXm91h7t1X791gQR2CU22GRt1jZ32CEhzooN04KTvjZcMjfAlpI915R9cuz8EZg9dIvtfSzs0wPx2cMV2otT2F5X2iEx0Kit2XzzACMAuR1HEDCgtwFgx+U82hPHABHtEbZd0biNk7utXCXz28ol3NVM3AA9EiYtcwvACMtdN0wwAg7/ydoC0QBPOlxxUMVkzQjf3W41TRDXfXLZvd1w093fXTLiPV3lfcdvIwHojXYjodRuRozwnd9nkN4tc7ozTNjHaHMx8GMY4d9lBuA0JwEDnl0Fnl0HTtYJLnMLrtXYnc6KFgGy7asF8QLprb0Ah8zeLXMlIAMeodb4tgAePs8h7twjXuIXcOKXcwUpfnIrjte1jHcj4MtUjQFvcIQLcNwCkb8WPsmLo9vpTWoQMAMekdgvHuTMXOTDiOQAoOTThbxCDjdOfnJRftnS/OBW/uGIPJjsSxDkG14McOZQueP4drcbcdrtBuNf/jaVrObiy+bS/OZ57jZhPnF03hHJfWx4/+7GcHxg1UsQM3DEypXo5yfnx8YAiIDc7+xicG46e8zozevokD5ckh7nT15mlh4S7S1um3459LsGFCYCUk4QDfDj6AXj2zzppT5jG80Rqa5ro87pF+DqBwbrBTHrmn7rpI5vu+4RDs6Gqz45p7Da4VUCXwoCW72Q+ux9I5Dp6PWXHdHs6FUAz7440W7D017t117r2T7p3B5e3t7i6a5rTL7ZI2Du4bXhUwOUw7XX6Avu4eUFjEwRLk5q857b9T5j+G41+j5b/H456HdsAI/YtA5s3lYJlI5eu3UQAueDHj3VZHtsWqsRVC7vqGbxub5cPbPx6BXUHl9z7RbyHGHnJP9fOxKQ4QdWW4FlEAjzznHd8lOra5adETJP8NVs82zIWwWx8yTW872Db0G/EYc+85O98NR1ygPhYCsP26ODbykAzhkR9URP2B9A9cRlWwmB9eFlAFr/8cDW9R/R6wTPxlVN3dP1YlZPEGgfXmvfv/6eXUfO6xTtZgMg91ZNYnbPEHmfXXs/hH1f91quEY0/XWuAASvtCVeNArGO+B02Y9LNNxgg7OrdyBM3+ZV/+Zm/EIk/XZ1vN5//uR5h7Rz3BtJWNw7Q0yQGAWkAEamvXPfNN0zwBhyX1RcB+xMn+/Rn+xSG+7q/+STW+3bz+8Ef8BQhAxOP6AMggFx5AXFAZO//9hC7P1wXbpYnP2N3fRHUj3fXP4D0u/1VxuBnz/wUFv4ZNP4kVv4ZMQNlXmYHoILYDxACtFzgEMDgQYQJAxzA0QbAQ4gRJUZEMKCAQowGOVzQIkDACQkDlBzIWNJkAAg5Jq5kKXEGhJMxEx5QMkDCCY8DC8o0yNBhy5YVL/Lc2PFjyJE8eaYE2pTljQ1KldIcUHXATp4GUIBxGtSiUg5WRZKUKrNAi65doZaVSdUqVplauaadKBSs2KRsT56lmxYRA72BebII0nelXcGJMTJ4YbjlX8WRFRJ2LBGx5MiMKwMdYAAzZhE8Jmym+PWz4gGkJXY+HTn0aNUALrfWmzp2/8QJA2gnLtAjwe2HFRfs1hujwe3cxAP3/g1cuPKyxoE/bOAFetkFA0BMfwgDhefrMksguF09vNLs27l7B3/e5HjuPxS4j6kVBneILUTQN8k0tnz+TLIPv4f0CzAj/4DLAaYDMRIBLQIBmGCFFBpMiK/YFrRQoQcjlJDCDQ/CELgWKgzRoBRWgC3CQnBoz0LNYivxRBRV9BCAFl9sMEbgXhjuRANwKOTGh8AogUbbVPORxiCHJNJIJLnTjcYS5iJyAh2iCtGH41Sb8sQqiXwISy035BK4BL7ccAMdViQShAHIspAF8khLk0Y23bwRTjkbpBO4Bjg58QDtxIyIgvk2hP/ACtUCHbRQQx9CNMRFAT0yxBKAiBSiNPsMkIEmGr10w0w3fajTDUEF7pFEYbTRVAAmtfCAFVRjNUQGXjVV1gZpVZBBC9W4D1YAULXQN9I03FBYYouNc0NkY7sB2AM3qKFZSVs9EIkuK5t2zWux5XXbbklrAbAGgywXVmMPFKEIc9E9UF1snfWUvndvQ0PeAEWoot5sLSygsM32tdBfgGPVlr+Bb3v2QEKbq7dd/hjYgrSHA4w4YYrps9hhC0tNGIBvG0zSMTX5Eznhkg88ubIEethRV4AbwOFYifuKeWY9sbUZ50atO5DZkR/iYagAvVg3LfOGHrbooxtUWjUZRqX/z9qiIUIAhQZLkKGyqqsNN+utu/6atJcCpDfrh1bg1z0IZqgsbf7WZtvtA+NWzRFqz0OY7YeKWPg8CBypjO9+/wUcAMHzNpy0Kkx0b+PF00TavRQUNyxy/igH3PIAM1fNYPoUoGBxrU1zjwE0KiPdPdNRD07181hXbYV7lfMc9dmu89Ux3OnbffHeofu9suRKP1321C+/7uWukod9eeZlo/150mTg2r0CBsiZ+eKJg94p7enr/nvZw99t/LSA2O+87uusvvnz2AfKfe4HkH9+650XnzQeSA468eOfZQaggNydxnuGCSD89FfA0iDweehLC2uMp4AHQjAiCaDAARMo/5nY9cWCusPg/jTIQQ8qJ4Qou+AAKEDBE3awTK0hlGFSRkMMvlCDK0HhDE9Tw8rcEDMpYIELYbjDh4DgBSzQEWbsxxIhSoaIRkRiS5TIxPVtJoqCOQAEdlCDGRyximMKghp+pEAb0tCLYBTjGCdQxjN+5omcmUMBmigVBmxAAT4YQBDONsauwGAAPlDABt6mFAMUYA5isWEd76iUPO6xj38EZFMESUhDBiaRi7TKZiaAgCiIBQUiSMEjDRJJPurgBj9YWiWd0oAf3EAHYrEKJhlggBSIAAW0HEAUENCztHwylFYZZSlNgsoBqJKVrjQMLGXJy0EWEjDIFIsvgamaCW3IAAg8gKZYlNlKZgIqlrPkARBkcM3pZHOb3bTKN8PpIWfO0p3vpGc97XlPfOZTn/vkZz/9+U+ABlSgAyVoQQ16UIQmVKELZWhDHfpQiEZUohOlaEUtelGMZlSjG+VoRz36UZCGVKQjJWlJ+xkQADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel, during forced expiration, the intrathoracic intratracheal pressure (P",
"    <sub>",
"     tr",
"    </sub>",
"    ) is less than the pleural pressure (P",
"    <sub>",
"     pl",
"    </sub>",
"    ), worsening the obstruction. Right panel, during forced inspiration, P",
"    <sub>",
"     tr",
"    </sub>",
"    exceeds P",
"    <sub>",
"     pl",
"    </sub>",
"    , lessening the degree of obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Kryger M, Bode F, Antic R, et al. Am J Med 1976; 61:85.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15214=[""].join("\n");
var outline_f14_54_15214=null;
var title_f14_54_15215="Martin forceps";
var content_f14_54_15215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Martin tissue forceps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 160px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Martin forceps have a broad tooth-gripping surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_54_15215=[""].join("\n");
var outline_f14_54_15215=null;
